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Hospital acquired Staphylococcus aureus bacteraemia presents a serious health risk to 
inpatients, due to the high risk of transmission and high mortality rates, which is in part is 
due to the emergence of multiple drug resistant strains of S. aureus. Therefore, the prompt 
diagnosis and treatment of S. aureus bacteraemia is of paramount importance in the 
Intensive Care department. 
Staphylococcal Protein A (SpA) is an immunoglobulin-binding surface protein, expressed by 
more than 98.9% of S. aureus strains, with a primary function of aiding S. aureus in the 
colonisation of the host. While many Staphylococcal toxins are excreted by the kidneys, the 
method of SpA processing and removal by the body has not been confirmed. If SpA is 
present in urine, it could provide a key marker of S. aureus infection. 
The aim of this research was to develop techniques for the detection of SpA in samples, and 
evaluate the surface protein as a target for S. aureus urinary antigen testing. This was to be 
assessed in a sample population of 45 Intensive Care patients, each providing up to 8 
samples over a 48 hour inpatient stay. 
An effective and specific Western Blot was developed for the detection of commercial SpA 
in both buffer and control urine; however, this method failed to detect any SpA bands in 
patient urine samples. Subsequently, an optimised ELISA displayed increased sensitivity, 
being able to detect lower levels of SpA down to 0.78ng/ml. Using this technique, we 
detected an increased absorbance in 25% of patient samples tested, implying the presence 
of SpA. However, these samples did not display the same characteristics as commercial SpA, 
lacking the heat-resistance of the purified protein when ELISA samples were subject to 
boiling. Additionally, the application of mass spectrometry to analysing the SpA ELISA 
positive samples did not identify SpA. Furthermore, positive ELISA results were significantly 
associated with renal failure, but not with markers of infection. 
This research represents a comprehensive analysis of immunoblotting and immunoassay 
methods for detecting SpA in urine samples. Further work is required to fully assess the 
route of excretion of SpA, and the techniques developed could prove useful in the testing of 
other clinical samples, such as serum, for SpA. 
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1.1 Staphylococcus aureus 
Staphylococcus aureus is a gram-positive bacterium, found commonly as a commensal 
organism in humans. It is capable of causing life-threatening illnesses, such as major, multi-
system infection and sepsis from contamination of wounds, or from invasive medical 
procedures. The organism possesses an extensive armoury of toxins and surface proteins, 
which help it to avoid eradication by the host defences. With the discovery and widespread 
use of antibiotics, the physicians became able to halt the progression from local S. aureus 
infection to widespread dissemination throughout the body. However, almost as soon as 
treatment through antibiotics became available, S. aureus began to evolve mechanisms of 
evading eradication by antibiotics.1 Through the evolution of these various antibiotic 
resistant strains, S. aureus remains capable of causing severe, and sometimes fatal, 
infections, and poses a significant challenge for medical professionals, particularly in the 
intensive care setting.2 
1.2 Staphylococcus aureus Microbiology 
S. aureus is a facultative anaerobic coccal bacterium, capable of both aerobic and anaerobic 
respiration.3 Most strains of S. aureus are positive for catalase, a digestive enzyme which 
characterises this particularly virulent species of Staphylococcus, though catalase-negative 
strains can also cause human disease.4 Observed through the microscope, S. aureus are 
small, round bacteria, which resembles a ‘bunch of grapes’ due to their lack of separation 
following asexual reproduction.5 Macroscopically, S. aureus forms large, circular golden-
coloured colonies; hence the alternative name for the bacterium, ‘Golden Staph’.4 
Many genetic variants (or strains) of S. aureus exist, of which 13 have been fully gene 
sequenced.6 While the majority of the genome consists of a highly conserved core-region of 
genes, up to 20% of genetic elements display high variability, capable of expressing a wide 
variety of differing virulent protein products.7, 8 This confers on S. aureus a significant 
adaptability to develop antibiotic resistance and aid pathogenesis. 
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1.3 Staphylococcal Cell Wall Morphology 
All Gram-positive bacteria, including Staphylococci, are encased in a thick, homogenous, cell 
wall formed primarily from cross-linked peptidoglycan molecules.9 In gram-positive bacteria 
such as S. aureus, these cross-links are glycosidic covalent bonds connecting glycan strands 
of the peptidoglycan molecules (glycine interbridges).5 A strongly cross-linked cell wall 
serves two important purposes for S. aureus; it provides a rigid casing to prevent osmotic 
lysis of the cell,10 and it provides anchorage for surface proteins.11 Peptidoglycan makes up 
approximately 50% of the cell wall mass, with the other largest component, teichoic acid, 
making up around 40%.12 Teichoic acids, including cell membrane associated lipoteichoic 
acid,  extend from the peptidoglycan layer and confer a negative charge on the S. aureus cell 
wall (Figure 1).12, 13 
 
Figure 1- Schematic representation of the S. aureus cell wall, with the solid horizontal lines representing cross-
linked peptidoglycan, and the wavy vertical lines representing teichoic acids projecting through the cell wall. 
Image adapted from Umeda et al.
13
 Permission for use allowed by American Society of Microbiology. 
 
The remainder of the cell wall components include surface proteins and receptors. As well 
as a rigid cell wall, over 90% of S. aureus strains posses an external polysaccharide capsule,14 
which has been shown to reduce opsonisation and phagocytosis by shielding antibody 
binding sites (such as immunogenic teichoic acids), from the immune system.15 
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1.4 Staphylococcus aureus Infection 
1.5 Staphylococcus aureus Pathogenesis 
S. aureus is human pathogen responsible for infection at a wide-range of sites, in 
particularly infections of the skin and soft tissues, bones and the bloodstream.16 It is the 
presence of S. aureus in the bloodstream (bacteraemia) which disseminates the organism to 
sites of infection, and also leads to the most serious and life-threatening sequelae of S. 
aureus infection: endocarditis and sepsis.17 
S. aureus bacteraemia results from invasion from the external environment, either due to 
breaks in the skin or from the presence of foreign bodies.3 Evidence shows that the risk of S. 
aureus infection increases in the presence of foreign material, which in the community takes 
the form of contaminated dirt or clothing, and in the healthcare setting can result from 
sutures, intravascular devices or urinary catheters.18, 19 Whether this initial colonisation of S. 
aureus progresses from local to metastatic infection is dependent on interactions between 
the host endothelial cells and the bacterium.17 In a review of S. aureus infection 
pathogenesis by Archer et al, the progression of S. aureus infection is summarised in 5 
stages: colonisation, local infection, systemic dissemination/sepsis, metastatic infection, and 
finally, toxinosis, the system-wide spread of toxins.20  
1.6 Intracellular S. aureus infection 
S. aureus was traditionally described as a wholly extra-cellular organism, causing local and 
systemic infection through adherence to endothelial cells and the release of exotoxin.4, 21 A 
study investigating S. aureus in aortic endothelial cells showed that S. aureus has the ability 
to propagate and prolong infection through the intercellular route.22 These findings led to 
the description of the primary mechanism of S. aureus cellular invasion, which involves the 
adhesion of S. aureus  to endothelial cells through the activity of fibronectin-binding surface 
proteins FnbpA and FnbpB.23  
As well as active invasion of endothelial cells, S. aureus has also been shown to survive in 
specialised immune phagocytes, such as monocytes.24 The mechanism by which the 
bacterium survives phagocytosis once inside the cell is not fully understood, but is 
understood to involve both shielding by the polysaccharide capsule (if present), and the 
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release of virulence factors which can break down endosomes.16 The clinical implications of 
S. aureus internalisation have yet to be clearly defined, with some studies suggesting that 
the virulence of a strain is increased by its ability to internalise, and ultimately kill, host 
cells,25 while others suggest a link between recurrent S. aureus infection and intracellular 
survival.26  
1.6.1 Staphylococcal Nasal Carriage 
The most common site of colonisation of S. aureus, a natural commensal organism of 
humans, is the nose (nasal carriage).27 The epidemiology of S. aureus nasal carriers has been 
categorised into permanent carriers (10-35%), who exhibit constant nasal carriage, transient 
carriers (20-75%), who only exhibit temporary carriage, and finally, permanent non-carriers 
(5-50%).28 This means that at any one time, in a population of healthy individuals, around 
35% of the population will harbour S. aureus in the nasal passage, either permanently or 
temporarily.29 The nasal carriage of S. aureus is clinically important due to its effects on 
propagating and initiating S. aureus infection; it has been demonstrated to significantly 
increase hand carriage of the organism, and the risk of subsequent S. aureus infection 
following surgery is increased in patients known to be nasal carriers.29 Persistent nasal 
carriers and the general population tend to demonstrate differing S. aureus colonisation 
sites (Figure 2).30 
 




Figure 2- Sites and frequency of S. aureus colonisation of the general population and persistent nasal carriers. 
Image from Dancer at al.30 Permission for use in MSc thesis granted by Elsevier (License number 
3956002030720) 
 
Due to the increased risk of exposure, antibodies to staphylococcal toxins have been found 
in significantly higher levels in permanent carriers of S. aureus,31 and it has been suggested 
that this leads to the, paradoxically, improved infection prognosis in this group.32 
1.6.2 S. aureus Bacteraemia 
S. aureus is a common blood-stream pathogen, and bacteraemia is one of the most well 
recognised sequelae of S. aureus infection.33 The annual reported rate of S. aureus 
bacteraemia in the UK was 9,533 in 2013, 34 and despite increased awareness of antibiotic 
resistant S. aureus, and widespread application of transmission prevention schemes, the 
mortality rate for this condition remains high. In a large US study of 6,697 patients with 
blood-stream infection, S. aureus accounted for the highest crude mortality rate (22.5%) of 
all bacterial causes of septicaemia.35 In the UK, mortality amongst patients with diagnosed S. 
aureus bacteraemia is equally high (29% 30 day mortality), and higher still in those with 
identified MRSA infection (34% 30 day mortality).36  
The most considerable risk to ICU patients is from S. aureus sepsis, the stage of infection 
beyond bacteraemia, where the disseminated organism provokes a damaging immune 
response, and, in the case of severe sepsis, causes end-organ damage through ischemia.37 
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Effective recognition, diagnosis and treatment of S. aureus bacteraemia are essential for 
reducing the burden of this disease. 
1.6.3 Risk factors for S. aureus Bacteraemia 
Traditionally, S. aureus bacteraemia has been an inpatient-based (particularly intensive 
care) complication. patients are at high risk of bacteraemia due to a combination of existing 
susceptibility (i.e. immunosuppression) and high risk of exposure from other patients.38 
Additionally, invasive procedures, all of which are capable of introducing organisms into the 
bloodstream, are commonly performed in ICU wards. The endogenous route of infection, 
i.e. from the patient’s own flora, is thought to be responsible, (at least in part) for 80% of 
cases of Staphylococcal bacteraemia.39 A large study of non-surgical patients found the 
relative risk of developing Staphylococcal bacteraemia was 3.0 in persistent nasal carriers 
compared to non-carriers.40  
Recently, it has been identified that community antibiotic-resistance is on the rise, which is 
a worrying finding as it presents a reservoir for antibiotic-resistant organisms.41 There is 
potential for the transmission of such organisms from the community to the hospital 
setting.  
The primary infection which most commonly lead to S. aureus bacteraemia include 
pneumonia, osteoarticular infection, skin and soft tissue infection, infective endocarditis 
and intravenous catheter infection.33, 42 Therefore, patients at risk of S. aureus bacteraemia 
include those with compromised immunity, such as HIV positive patients,43 and those 
undergoing recurrent IV access, such as IV drug users or haemodialysis patients.44 45 
Additionally, these patients are among those particularly susceptible to community-
acquired bacteraemia.  
Considering Urinary Tract Infection (UTI) as a source of bacteraemia, S. aureus is rarely a 
direct pathogen of the urinary tract; in a study of urine samples from patients with 
symptomatic UTI, S. aureus only accounted for 0.5% of isolates.46 However, multiple studies 
have demonstrated that the asymptomatic presence of S. aureus in the urinary tract 
(bacteriuria) can lead to the development of S. aureus bacteraemia.47 48  
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The reverse case, where an S. aureus bacteraemia causes a subsequent bacteriuria, does 
appear to occur in cases where the initial site of infection is not the urinary tract.49 Studies 
demonstrate that concomitant S. aureus bacteriuria in patients with bacteraemia is 
associated with higher incidence of early complications from bacteraemia,50 and a higher 
incidence of admission to ICU.51 
Complicating the assessment  of S. aureus bacteriuria on ICU wards is the fact that S. aureus 
urinary tract colonisation can be viewed as a common consequence of urinary 
catheterisation, especially from long-term indwelling catheters.33 In one study of 127 
confirmed S. aureus bacteriuria cases, 73% were associated with catheterisation or internal 
urinary tract procedures.52 Therefore, it would be difficult to determine whether the 
bacterinuria is a direct result of presence of S. aureus in the bloodstream, or simply due to 
contamination from urinary tract intervention. 
1.6.4 S. aureus antibiotic resistance 
Antibiotic-resistant strains of S. aureus identified in ICU departments between 1996 and 
2009 suggest that a rate of 12.7 new cases of MRSA bacteraemia arise every 1000 days 
spent on ICU.53 In recent years, antibiotic resistance has become the single most important 
issue affecting S. aureus infection in ICU departments. 
Antibiotics, in the form of penicillin, dramatically decreased mortality rates from 
Staphylococcal bacteraemia when they were first introduced in the early 1940s.54 However, 
within 2 years, penicillin-resistant strains of S. aureus were discovered.1 These were found 
to be caused by a Staphylococcal enzyme (β-lactamase) capable of breaking open the β-
lactam ring of the penicillin molecule.55 Widespread use of penicillin has eventually led to a 
resistance rate of over 90% in human isolates, effectively rendering the drug ineffective in 
treating S. aureus infection. The β-lactamase-resistant antibiotic methicillin was introduced 
in 1959, and the first reports of Methicillin-Resistant Staphylococcus aureus (MRSA) were 
published 2 years later.56 The mechanism of methicillin-resistance in MRSA occurs through 
the action of an independent penicillin-binding protein (PBP),57  which provides MRSA with 
resistance to all β-lactamase antibiotics, including cephalosporins and carbapenems. There 
is longitudinal and meta-analysis evidence that increased use of these antibiotics is 
associated with increased incidence of MRSA in the hospital setting.58, 59 In the UK at the 
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turn of the 21st century, almost half of S. aureus strains causing bacteraemia were β-lactam 
antibiotic resistant.60  
 
The clinical impact of this broad antibiotic resistance is of particular importance in hospital-
acquired S. aureus infection; invasive medical devices are the most common source of MRSA 
infection in UK tertiary centres,42 and infection with a resistant form of S. aureus increases 
length of stay in hospital and mortality rates.61 In UK ICU units, MRSA accounts for 58-60% 
of all S. aureus strains isolated.62 MRSA currently remains susceptible to glycoprotein 
antibiotics, such as vancomycin, and the use of vancomycin rapidly increased from 1980 
onwards in order to deal with such resistant infections.63 However, such selective pressure 
has led to the emergence of further resistant forms of S. aureus, including Vancomycin-
resistant Staphylococcus aureus (VRSA),64 indicating increasing difficulty in the 
pharmacological management of nocosomial S. aureus infection. 
1.6.5 Treatment of S. aureus bacteraemia 
Protocols for the initial management of S. aureus bacteraemia on ICU wards call for 
adequate and thorough clinical examination, followed by demonstrating direct evidence of 
bacteraemia with positive blood cultures.65 Alongside blood cultures, transoesophagael 
ultrasound is recommended in order to assess heart valves for vegetations, or for other 
primary sites of endocarditis.65 
Optimum treatment combines both medical management, in the form of antibiotics, and 
surgical removal of infectious loci, if identified.66 Although 10-40% of patients do not have 
an identifiable loci of infection, such as prosthetic heart valves or joints,67 early surgical 
intervention is proven to improve outcomes in appropriate patients.66 This further 
emphasises the need for quick diagnosis of infection, in order to assess if surgical 
intervention is required. In terms of antibiotic treatment, current UK recommendations in 
the UK suggest a combination antibiotic therapy, using a glycoprotein, and either linezolid or 
daptomycin, intravenously, for at least 2 weeks.68 However, best outcomes, with fewer 
recurrences of infection, are achieved with 4 or more weeks of antibiotic therapy, especially 
if there is concurrent endocarditis.66 
SID: 33007675                                                                                                                        Christopher Varley 
19 
 
1.6.6 Diagnosis of S. aureus infection 
The gold standard of S. aureus bacteraemia diagnosis is blood cultures, of at least two 
samples taken from two different sites of venous access. With 2 samples, this technique has 
80% sensitivity for detecting pathogenic organisms; to achieve >99% sensitivity, 4 or more 
samples should be taken, over a 24 hour period.69  
As well as confirming S. aureus infection, blood cultures also provide useful prognostic 
information. Positive blood cultures for S. aureus, taken more than 3 days after starting 
optimal antibiotic therapy, is the strongest indicator of complicated bacteraemia, even more 
so than the antibiotic resistance status of the organism.70  
1.7 Urinary Antigen testing 
The clinical practice of testing for urinary antigens in order to diagnose infective disease is 
well established. Current examples include the immunochromatographic membrane test 
(ICT) for Streptococcus pneumoniae cell wall glycoprotein antigen,71 and the indirect 
immunofluoresence test for Legionella pneumophila serogroup 1 antigen.72 With S. 
pneumoniae antigen testing, both the sensitivity and specificity is high of antigen detection, 
at 90% and 94% respectively.73 The alternative, sputum cultures, like blood cultures, can 
take more than 24 hours to provide diagnostic information, and organisms may be 
undetected in cultures following antibiotic use.74 An additional benefit is that urine testing is 
non-invasive, which is important in avoiding the risk of nocosomial bloodstream infection. 
However, in these conditions, it has been suggested that urinary antigen tests should be 
used in conjunction with blood or sputum cultures, which can provide antibiotic sensitivity 
information and can exclude other infectious agents.73 
Antigen testing for S. aureus infection has not currently been developed as a clinical test, 
despite the array of potential excreted and surface antigens that have been identified. In 
the literature, attempts to identify S. aureus virulence factors have been focused on 
detecting antigens in serum samples.75, 76 Using ELISA techniques, Azuma et al found 
staphylococcal superantigens in the serum of 42% of patients with confirmed sepsis on an 
ICU ward (n=78),76 providing evidence for the concurrent presence of S. aureus virulence 
factors and bloodstream infection. However, these have not progressed to clinical trials to 
put these tests into practice.  
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Similar techniques have been used to sensitively detect exogenously added Staphylococcal 
Enterotoxins in buffer and control urine, proving ELISA techniques capable of detecting 
small amounts of Staphylococcal toxin in urine.77, 78 Testing patient urine for endogenous 
Staphylococcal toxins has been achieved by Harrison et al, who identified the presence of 
superantigens Toxin Shock Syndrome Toxin 1 (TSST-1), Staphylococcal Enterotoxin B (SEB), 
Staphylococcal Enterotoxin C (SEC) and Alpha-haemolysin (AH) in 9/101 infant urine 
samples, again using an ELISA technique.79  
Based on the work by Harrison et al, this laboratory developed ELISA and protein 
immunoblotting (Western Blot) methods for detecting Staphylococcal toxins in ICU patient 
urine. Frances Price (MSc 2013) recruited urine samples from 45 inpatients in an ICU 
department and tested for four Staphylococcal toxins: TSST-1, SEB, SEC and AH.80 The 
results of Western Blots found high proportions of patient samples contained AH (72%), 
with lower levels of other toxins SEB (21%), SEC (7.5%) and TSST (5.9%). These positive 
samples correlated with clinical indicators of infection; patients positive for AH had higher 
levels of serum white blood cells, increased temperature and a higher chance of having an 
infective diagnosis. These data provide evidence of S. aureus toxin presence in urine, as well 
as a foundation for the testing of ICU patient urine for other potential antigens. 
1.8 Staphylococcus aureus- Virulence Factors 
Aiding S. aureus in its survival and propagation in the human host, both extra- and 
intracellularly, are a suite of pathogenic molecules, known as virulence factors.81 These aid 
S. aureus in killing or invading cells, anchoring to connective tissue or endothelial cells, and 
evading the complex human immune system, all of which are vital functions if any 
microorganism is to thrive within host tissues. Virulence factors are secreted from the cell, 
in the form of enzymes or exotoxins, or exist as surface proteins which allow S. aureus to 
directly interact with the host via the cell wall of the bacterium. 
1.8.1 Enzymes 
The most basic, though directly damaging, virulence factors utilized by S. aureus are 
digestive enzymes, of which this particular pathogen has a large variety, including catalase, 
proteases,  nucleases, lipases, hyaluronate lyase and staphylokinase.20 These are used to 
directly invade host tissue, or predispose conditions for bacterial growth; e.g. provide 
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nutrients or trigger clotting of blood around invading organisms, in order to shield them 
from the immune system.4 These basic functions are vital for microorganism survival, and 
are also secreted by a variety of other pathogenic bacteria. However, the production of 
catalase is useful for distinguishing between Staphylococci and Streptococci, which is 
catalase-negative, and another commonly isolated Gram-positive bacteria.82  
1.8.2 Exotoxins 
Exotoxins are a family of extracellular proteins produced by S. aureus, as well as many other 
Gram-positive bacteria, which are known to have both deleterious effects on the host 
immune system and biological effects promoting the propagation of the bacterium.83 As 
opposed to endotoxin (lipopolysaccharides), which are primarily found within Gram-
negative bacteria and are released on cell lysis, exotoxin in actively secreted by bacteria.84 
There are 2 major functional groups of exotoxin, cytotoxic molecules and toxic 
superantigens: 
1.8.2.1  Cytotoxic molecules 
This functional group includes molecules capable of killing host cells; the haemolysins 
(alpha, beta, gamma and delta) and Panton-Valentine Leukocidin (PVL). The previously 
mentioned Alpha-haemolysin (AH), also known as alpha-toxin, was the first exotoxin with 
cell membrane pore-forming qualities discovered.85 It binds to the membranes of a variety 
of host cells, including erythrocytes, monocytes and endothelial cells, and creates a 1-2nm 
wide hole in the membrane through the formation of a heptameric pore.86 Pore-formation 
is directly damaging to the cell membrane, and disrupts the osmotic balance of the cell. In 
sufficient quantities (>1µg/ml), AH-pore formation can cause cell death very rapidly, 
especially in blood cells such as macrophages and erythrocytes.85  
PVL is an S. aureus exotoxin responsible for leukocyte destruction and tissue necrosis.87 
Although the gene for PVL was found to be expressed in <5% of S. aureus strains, 88 it was 
found in 93% of strains isolated from primary necrotizing infections of the skin (such as 
furuncles).87 This demonstrates a particularly specialised role for this virulence factor in skin 
and soft-tissue infection; the gene encoding PVL is rarely, if at all, located in S. aureus strains 
causing deep-seated infections such as pneumonia or sepsis.89 This clearly demonstrates the 
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ability of S. aureus to vary its genetic ‘loadout’ in order to suit the challenges of surviving in 
different body tissues. 
1.8.2.2 Toxic Superantigens 
Toxic Superantigens (TSAgs) are a group of Staphylococcal exotoxins, which share a common 
set of biological functions, although separately they cause distinct clinical syndromes, 
without the need for overt S. aureus infection. Included in this group is the protein 
responsible for Toxic Shock Syndrome, TSST-1, and the Staphylococcal Enterotoxins (SE), 
which cause emesis and gastroenteritis.90 There are up to 19 different variants of SE, though 
commonly studied examples include SEA, SEB, SEC, SEE, SEH.91  
Despite their varied clinical effects, TSAgs are named after the superantigen effect which is 
common to this group; this is defined as the ability to bind to T-cell receptors regardless of 
antigen specificity. 92 The result of this superantigenic binding is to activate large numbers of 
T-cells in the host, and promote clonal proliferation of those cells.93 In certain cases, TSAg 
stimulation of T cells causes a ‘cytokine storm’, defined as sustained over-production of 
interleukin-1, interleukin-2 and tissue necrosis factor.94 This is the pathological basis for 
toxic shock syndrome, a potentially fatal complication arising from the presence of S. aureus 
growth in areas such as the genitourinary tract, or surgical sites. 
The exact reason for deliberately activating adaptive immune system cells is so far 
unknown; subsequent T-cell anergy following clonal proliferation was long proposed as a 
potential pathogenic effect, following the observation of T-cell unresponsiveness in-vitro 
when subjected to SEB. 95 However, in a recent study of T-cells in active toxic shock 
syndrome, patient T-cells displayed as much activation in response to further exposure to 
TSST-1 as disease-free controls.96 This suggests that host T-cells do not become fully anergic 
during active superantigen toxicity, as they are able to respond to further challenge by 
superantigens. 
1.8.3 Surface proteins 
Surface proteins, covalently bonded to the peptidoglycan of the cell wall of S. aureus, play a 
significant role in the pathogenesis of bacteraemia and sepsis, in particular by evading the 
immune system in the bloodstream.97 All S. aureus cell-wall anchored (CWA) proteins share 
similar basic features allowing their incorporation into the cell wall; at the amino terminal 
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are secretary signal peptides which bind to the cell membrane secretory apparatus, and are 
subsequently removed during secretion.98 At the carboxyl terminal, each CWA protein has a 
sorting signal which facilitates the adherence of the molecule to cell wall peptidoglycan.99 
The predominant family of CWA proteins is the microbial surface components recognizing 
adhesive matrix molecules (MSCRAMM), which contains virulence factors Clumping factor A 
and B (ClfA, ClfB), Fibronectin-Binding Proteins A and B (FnBPA, FnBPB) and collagen adhesin 
(Cna) (Table 1). 98, 100 101 These proteins, as the group name suggests, have primary roles in 
binding to host extra-cellular matrix (ECM) molecules, an important step in the pathogenesis 
of S. aureus soft tissue and blood stream infection.100 Other groups include Near Iron-
transporter (NEAT) motif proteins, which are proteins involved in the capture of iron from 
haemoglobin.102 The sole three-helical bundle CWA protein, Protein A, which is also not an 
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CWA Protein CWA Group Ligand Function 
Clumping factor A 
(ClfA) 
MSCRAMM Fibrinogen- γ-chain 
carboxyl terminus 
 




evasion by binding 
soluble fibrinogen 
Clumping factor B 
(ClfB) 
MSCRAMM Fibrinogen- α-chain  Adhesion to 
desquamated 







Complement Factor H 




MSCRAMM Fibrinogen- α-chain Adhesion to ECM 
Fibronectin-binding 
proteins A ( FnBPA) 
and B ( FnBPB) 
MSCRAMM Fibrinogen- γ-chain 
carboxyl terminus 
Adhesion to ECM 
Collagen adhesin 
(Cna) 




NEAT protein Haem , fibrinogen , 
fibronectin, 
cytokeratin 10, loricrin 






for platelets (SraP) 
NEAT protein Salivary agglutinin 
gp340, unidentified 
ligand on platelets 
Pathogenesis of 
endocarditis 
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1.9 Protein A 
Staphylococcal Protein A (SpA) is a CWA protein found in 98.9% of coagulase-positive S. 
aureus strains,103 and makes up 1.6% of the mass (6.7% cell wall mass) of cultured S. aureus 
colonies.104 It is a unique product of S. aureus; it is not produced by other Staphylococcal 
species such as S. epidermis.105 It is found primarily on the bacterial cell wall, and also in the 
culture supernatant as extracellular SpA.106 The most distinctive feature of SpA is a strong 
IgG-binding capacity, which facilitated its discovery. It was initially described in 1940 by 
Verwey et al,107 as a protein fraction obtained from Staphylococcal extracts, capable of 
precipitating antibodies from rabbit sera. Designated ‘Antigen A’, SpA was later confirmed 
to be a bacterial cell wall protein,108 the first such discovered, and the antigen fraction as 
described by Verwey was given the name ‘Protein A’ in 1964.109 From further antibody 
precipitation tests on SpA, it was found that SpA strongly binds the Fc portion of IgG 
antibodies, in reverse of the usual antigen-antibody binding pattern.110  IgG is capable of 
penetrating the capsule of S. aureus to reach the cell wall, and study comparing 
encapsulated and non-encapsulated S. aureus variants showed an equal binding capacity 
between SpA and free IgG.111 Later studies also confirmed an ability of SpA to also bind to 
human IgM, specifically the Fab VH3 subclass.112 A description of the structure of the SpA 
molecule will aid in the understanding of this antibody-binding capacity.  
1.9.1 Structure of Protein A 
Cell-wall bound SpA, as isolated from the Cowan I strain, was found to be a 42kDa sized 
surface protein.113 However, variations of SpA have been discovered, which encompass a 
range of molecular weights.114 In a study by Cheung et al, cell wall extracts from 12 different 
strains (not including Cowen I) were purified and tested by Western Blot, which identified 7 
distinct SpA variants, ranging from 45-57kDa in size.114 This was theorized to be due to 
variations in the protein structure of SpA. There is also a difference in MW between cell-wall 
bound SpA and extracellular. The most commonly studied SpA-producing strains, Cowen I 
and 8325, produce cell-wall bound SpA at sizes 52kDa and 53kDa respectively, while 
extracellular SpA is smaller, secreted by strain A676, measured at 41kDa by equilibrium 
sedimentation.100, 106, 115 116 
This main functional section of SpA is comprised of 4 or 5 IgG binding domains (IgBDs), 4 of 
which are highly homologous.116 The IgBDs, designated EDABC, are proceeded by an N-
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terminal signal region, and followed by an X-region, formed by 1) a variable repeat region 
(XR) and 2) an end C-terminal sorting signal region (XC).
117 As SpA is a CWA protein, the C 
terminal region contains the characteristic cell wall binding section. The SpA molecule is 
synthesised as a precursor molecule with all these regions intact (Figure 3). 
 
Figure 3- Structure of SpA- molecular structure consisting of an N-terminal signal peptide (S), 5 IgG binding 
amino-acid sequences (EDACB), and an X region, consisting of a variable region (XR) and a C-terminal (XC). 
Figure adapted from Sorum et al.
117 
Permission for use in MSc thesis granted by Oxford University Press 
(License number 3953851085813) 
1.9.1.1 N-Terminal Signal Region 
The peptide found at the N-terminal is responsible for SpA joining the extracellular 
exportation pathway within the cell, and subsequently being incorporated into the cell-
wall.118 The particular route of secretion for SpA is known to be the general secretory (Sec) 
pathway, and the N-terminal signal peptide is cleaved during Sec translocation through the 
cell membrane.119 This method of protein sorting to the membrane is common to many 
surface and excreted bacterial proteins, and a large proportion bacterial precursor proteins 
contain a similar sized N-terminal signal sequence for this purpose.120 
1.9.1.2 IgG Binding regions 
The Immunoglobulin binding domains (IgBD) of SpA are 58 amino-acids long, and each 
comprises a triple α-helix structure, with the complete tertiary structure consisting of each 
triple helix folding together, as opposed to a straight string of regions (Figure 4).  
 
Figure 4- SpA IgBD B, ribbon diagram demonstrating triple-helical structure, image from Lambris et al.
121
 
Permission for use granted by Nature Publishing Group (License number 3956030424775) 
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The ability to bind to the Fc portion of antibodies occurs through contact on helices I and 
II.121 Total binding capacity of SpA allows two IgG molecules to bind to each SpA molecule 
(molar ratio 2.1:1).122 The crystal structure of this antibody-domain complex has been fully 
described between domain B and Fc, which has demonstrated two points of contact, one 
hydrophobic and one polar, between the CH2 and CH3 regions of Fc fragments and domain 
B.123 All individual domains can bind to the Fc portion of IgG, as well as the Fab region.124 125 
However, not all regions bind equally; regions A, B, C and D are all highly homologous and 
demonstrate strong binding to IgG, while region E has a weak affinity for IgG, and was only 
discovered via genetic sequencing of strain 8325. This confirmed the complete Ig-binding 
regions of SpA to be pentameric.116 Artificial SpA IgBDs exist, such as domain Z, engineered 
from naturally occurring domain B by replacing a glycine residue with an alanine residue in 
helix I.126 This molecule retains the IgG-binding affinity, and is able to be polymerized to 
form longer chains of IgG binding regions. 
Unlike the wide variety of human and animal IgG molecules which can bind SpA via the Fc 
region,127 the alternative Fab binding is specific to the VH3 (variable heavy chain) region 
within the Fab region of IgM.128 Binding to the Fab region occurs through IgBD helices II and 
III, binding to region VH3 of IgM antibodies (Figure 5).129 




Figure 5- SpA domain D binding to the VH region of Fab 2A2. Binding sites between helices II and III, and VH are 
labelled D, E and B. Image from Graille et al.129 Permission for use allowed in unpublished MSc by Proceedings 
of the National Academy of Sciences 
 
Different strains of S. aureus can express variants of SpA molecules with different 
combinations of IgBDs; these can include molecules containing only 4 IgBDs, missing region 
A or C.117 Referring to the SpA-producing S. aureus strain, Cowen I, it has been found to 
project 5 IgBDs from the cell surface, with the E domain closest to the N-terminal.116 
1.9.1.3 X-region- variable repeat 
The polymorphic XR region is located immediately before the C-terminal cell-wall binding 
region, and consists of a variable number of 24 base-pair repeats.130 The biological function 
of this region is not known, though it has been suggested that these repeats aid in extending 
the SpA molecule beyond the cell wall.131 The XR region varies between strains of S. aureus, 
and affects the molecular weight of the SpA molecule (Figure 6).117 




Figure 6- S. aureus isolates demonstrating variants of SpA, with variable XR regions, amino acid (aa) length and 
estimated molecular weight. These variants of SpA genes for identified from MRSA isolates in hospital patients. 
Diagram from Sorum et al.
117 
Permission for use in MSc thesis granted by Oxford University Press (License 
number 3953851085813) 
 
This region does serve a biomedical purpose however; the short sequence repeat (SSR) 
region of the SpA gene (spa), which encodes the SpA XR region present in most strains of S. 
aureus, can be sequenced in order to type S. aureus.132 This is the most common S. aureus 
typing method, due to its speed and ease of interpretation. One disadvantage of this 
however, is any variability in the 5 IgBDs can lead to a ‘non-typable’ result, which is known 
to occur due in 1-2% of strains due to natural mutation.133 
1.9.1.4 X-region- C-terminal sorting signal 
The C-terminal end of the SpA molecule is responsible for attachment to the S. aureus cell 
wall, allowing the SpA to extend from the bacterium.  The section directly responsible for 
this incorporation to the cell wall comprises a 35-residue sorting signal, in the form of the 
LPXTG motif.11 This is then followed by a tail of positively charged residues. Once the 
molecule containing the LPXTG motif is incorporated into the cell wall, a sortase enzyme 
cleaves between the threonine and glycine amino acid residues, allowing the free carboxyl 
group of threonine to bind to the peptidoglycan cross-bridges.99 Once this occurs, the SpA 
molecule is securely attached to the cell wall by the C-terminal, with the N-terminal region, 
including IgBDs, projected in an extended profile outside of the cell.  
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1.9.2 Extracellular Protein A 
Most strains of S. aureus produce SpA as both cell wall bound and extracellular protein; 
approximately 2-6 times more cell wall bound SpA is produced than extracellular,103 though 
some strains (particularly antibiotic-resistant strains) produce solely extracellular SpA.134, 135 
As described, known fractions of secreted extracellular SpA exist at a smaller MW than cell-
wall associated.100 
Extracellular SpA is produced and secreted during the exponential phase, as a fraction of 5% 
of total SpA, by Cowen I S. aureus.106 However, a large proportion of SpA in culture medium 
is the result of release from the cell wall during cell lysis.106 Despite this mixture of secreted 
and cell-wall lysed SpA, there exists evidence that the secretion of SpA is a controlled and 
deliberate act by S. aureus, induced by the external environment. One method by which SpA 
release is induced is through interaction with host chemokines, which has been 
demonstrated in MRSA skin infection in mice.136 
The method of SpA release is through a separate biochemical process through that which 
incorporates SpA in to the cell wall. One such process involves the action of the LytM 
enzyme, a secreted autolytic enzyme which degrades the cell wall of S. aureus by breaking 
cross-bridges of peptidoglycan.137 LytM is understood to be the final step in a process which 
releases SpA from the cell wall; however, LytM mutants continued to produce small 
amounts of secreted SpA, indicating that other enzymes facilitate the cell wall release of 
SpA.138 Another, independent route of release was confirmed recently by O’Halloran et al, 
as released SpA was detected with an unprocessed sorting signal, indicating no prior 
incorporation into the cell wall.139 This evidence shows that the secretion of free SpA is the 
result of a combination of enzyme-induced release from the cell wall and a distinct secretion 
pathway, indicating that extracellular SpA plays a useful role for S. aureus. Given the potent 
IgG binding capability of SpA , extracellular SpA may aid the cell-wall bound protein in the 
primary function of immune evasion. 
1.9.3 Functions of Protein A 
SpA is a multi-faceted virulence factor for S. aureus; its ability to bind host antibodies is 
SpA’s most understood mechanism of virulence, in recent years it has been demonstrated to 
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provide a variety advantageous effects which enhance the propagation of S. aureus. These 
can be grouped into: 
1. Preventing opsonophagocytic killing, by binding to Fc portion of host IgG 
2. Evasion of host adaptive immunity, through superantigenic activation of B-cells 
3. Adherence of S. aureus to sites of thrombosis and endothelial injury, though platelet 
binding 
4. Promotion of S. aureus aggregation and biofilm formation 
1.9.3.1 SpA binding to IgG Fc- prevention of opsonophagocytosis and complement 
activation 
Opsonisation describes the process in which host antibodies (with additional aid from the 
complement system) bind to an invading antigen, in order to clump together pathogens and 
provide increased recognition by the innate and adaptive immune system. The advantage to 
the host is that opsonisation aids phagocytosis of invading organisms by macrophages, a 
process with the combined name of opsonophagocytosis.140 The ability of SpA to bind to the 
Fc portion of IgG confers S. aureus the means to avoid opsonisation, by presenting the 
opposite end of the IgG molecule to the region which immune cells traditionally bind, i.e. it 
‘hides’ the usual antigen recognised by phagocytes (Figure 7).141  
 
 
Figure 7- Comparison of normal antibody-mediated phagocytosis and SpA evasion of phagocytosis from 
polymorphic neutrophils (PMN). Images adapted from Kobayashi et al.142 Permission for use allowed by 
American Society of Microbiology. 
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Experimental evidence demonstrates the effectiveness of SpA in preventing phagocytosis. 
Peterson et al demonstrated that S. aureus strains which expressed higher amounts of SpA 
were phagocytosed by neutrophils at a slower rate, when placed in an IgG rich 
environment.143 Setting this experiment in an IgG saturated medium ensures that SpA-IgG 
surface binding sites are saturated, proving that the reduction in phagocytosis is as a result 
of IgG binding. Furthermore, S. aureus strains displaying a variant of SpA, specially 
engineered to lack specific Fc binding capacity, exhibit reduced survival capacity in mice.141  
This technique of incapacitating the humoural immune system by reversing antibody 
binding patterns isn’t exclusive to S. aureus. A study involving another Gram-positive 
pathogen, Streptococcus pyogenes, showed that the orientation of antibody binding on the 
surface of a bacterium does influence pathogen survival in the host; wild-type S. pyogenes, 
expressing a Streptococcal IgG Fc binding protein (protein M1), survive longer and avoid 
host immune response longer than mutants lacking an IgG Fc binding capacity.144 This is 
additional evidence for IgG Fc binding acting as a viable immune evasion tactic for S. aureus, 
and the authors also suggest that IgG Fc binding plays a large role in the survival of 
pathogenic organisms as commensals in the healthy population.144 
Another potential virulent effect of this interaction with IgG Fc is the depletion of 
complement factor; the complex formed between SpA and Fc fragments has been shown to 
reduce complement factors in rabbit sera,145 but conversely, inhibit complement system 
activation.146 This subsequent inhibition of the classical complement pathway occurs 
through an unknown mechanism. 
1.9.3.2 SpA superantigen activity 
The ability of SpA to bind to the Fab region of IgM confers another route for S. aureus to 
disrupt the host immune response; it is the method by which SpA acts a superantigen.147 
The primary target of Fab binding, the VH3 class of IgM, is specifically expressed on the cell 
membranes of plasma B-cells.148 Following binding, SpA activates the B-cell and promotes 
clonal expansion and  the release of IgG antibodies.149, 150 This mechanism of lymphocyte 
interaction is similar to the S. aureus toxic superantigens discussed above; however, these 
bind to and activate T-cells only, implying a unique role for SpA in humoural immune 
activation. A recent study Goodyear et al, following the fate of peripheral B-cells activated 
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by SpA, discovered that, following a limited amount of clonal proliferation, these cells 
undergo programmed cell death.151 As well as disrupting antibody responses, memory B-
cells have also been proposed as a target for SpA, and murine studies has recently proven 
that SpA-expressing S. aureus ameliorates host adaptive immunity, reducing protection 
against S. aureus re-infection.141 As up to half of mature human B cells are capable of 
expressing the VH3-SpA binding site,151 this could present a significant virulence effect for S. 
aureus. 
Another proposed function of these superantigen effects is the ability to trigger an 
exaggerated immune response towards a specific antigen; this phenomenon is termed 
immunodominance, and describes the predilection of targeted immune responses towards 
one antigen (e.g. SpA) over other potential targets.152 SpA derived B-cell clonal expansion 
produces B-cell types with a bias towards the VH3 class of antibody receptor, which reduce 
the immune system’s ability to recognise the wider range of S. aureus virulence factors, and 
therefore leads to less protection from future infection.152 
Recently, it has been demonstrated that this B-cell superantigen effect subsequently 
activates CD4+ T-cells in lymphatic tissue, providing additional evidence of host immune 
manipulation by S. aureus.153 Whether this T-cell involvement helps or hinders S. aureus 
infection is yet to be investigated. 
1.9.3.3 SpA Platelet Binding 
A study of Staphylococcal platelet binding by Nguyen et al, demonstrated that platelets 
expressing the gC1qR platelet protein show preferential binding to S. aureus strains 
expressing SpA (e.g. Cowen I), and that beads of purified SpA can precipitate gC1qR from 
solution.154 This is an example of a novel method of platelet binding in S. aureus, an ability 
which aids the organism in localising to areas of endothelial damage or thrombosis. 
1.9.3.4 SpA Biofilm Formation 
Along with interactions with the host, SpA plays a role in multicellular behaviour in S. 
aureus, primarily the formation of biofilms. S. aureus mutants with the gene responsible for 
virulence factor expression in S. aureus, agr, deleted has been shown to form more stable 
and strong biofilms.155 The expression of this gene is inversely related to production of cell 
surface proteins, including SpA. Recently, Merino et al demonstrated that over-expression 
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of SpA specifically, both attached to the cell surface and secreted into medium, contributed 
to the initial formation of biofilms in-vitro and in murine infection models.156 These findings 
suggest a role for SpA in primary infections particularly important to ICU wards, those of 
intravascular and urinary catheters. 
1.9.4 Evidence for SpA as a virulence factor 
Several studies have confirmed the role of SpA as an important virulence factor in S. aureus 
infection. In experimental mouse models, SpA-negative mutant strains of S. aureus were 
demonstrated to produce smaller skin lesions and less severe intraperitoneal infection, than 
their SpA-positive counterparts.157 A greater degree of arthritis and bone destruction is seen 
in wild-type S. aureus expressing SpA as opposed to mutants lacking SpA, when injected into 
the synovial cavity.158 Further models of murine septic arthritis, demonstrate clearly that 
SpA  expressing S. aureus strains give rise to more severe infection and higher mortality 
rates, confirming SpA as a virulence factor in osteoarticular infection.158 
Along with direct evidence of the increased pathogenicity of SpA expressing strains, several 
studies have proved a correlation between SpA-depleted S. aureus mutants and reduced 
virulence.157, 159, 160 
The pathogenic effects of SpA have also been confirmed in other manifestations of S. 
aureus, beside direct infection. High levels of SpA have been indentified in S. aureus isolates, 
collected from patients with active Kawasaki disease, an autoimmune disease of childhood 
with suspected S. aureus sensitisation playing a role in pathogenesis.161 Similar immune 
disruption is seen in patients with Kawasaki Disease, as that caused by toxic superantigens 
(such as TSST-1).162 
SpA has a clear, demonstrable role in the pathogenesis of S. aureus infection, along with a 
wide range of proven virulent effects which primarily act on prolonging S. aureus survival in 
the host, avoiding and disrupting the immune system and directly damaging host tissue. 
1.9.5 Genetics of SpA 
The structural gene for SpA, spa, was first cloned into E. coli strains by Löfdahl et al.163 DNA 
sequence assays revealed 5 homologous regions corresponding to 5 IgBDs, which, when 
expressed, retained the ability to bind IgG. The gene was completely sequenced one year 
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later, using S. aureus strain 8325, which gave an estimated Mr for SpA of 58, 703.
164 
Depending on the strain of S. aureus, spa can be found primarily on plasmids, or on bacterial 
chromosomes. It should be noted that coagulase-negative strains of S. aureus, with plasmid-
encoded spa  have been found to produce only 12-30% of the SpA expressed by 
chromosomal spa strains, such as Cowen I.165 SpA is maximally produced during the 
exponential phase of growth, like other surface proteins; production is then down-regulated 
in the post-exponential phase.166  
1.9.5.1 Control of SpA expression 
S. aureus virulence factor expression, including exotoxins and surface proteins, is controlled 
by global regulatory systems, which are activated or deactivated at certain times of the S. 
aureus life cycle.167 These regulate the temporal expression of virulence factors by 
controlling the expression of multiple genes at once, and are in turn influenced by the 
quorum sensing system. On such system agr (accessory gene regulator), works at the 
transcriptional level through the action of a regulatory RNA molecule (RNA III).168 This global 
regulator gene was initially described as the genetic loci activated during the exponential 
phase of S. aureus growth; agr- knockout mutants display decreased secretion of the 
exotoxins AH and TSST-1, confirming its role in up-regulating virulence factor expression.169  
The genetic control of spa expression involves several transcription factors, which are also 
involved in the expression of other virulence factors. This system involves inhibitory factors, 
such as SarA (staphylococcal accessory regulator), and promoting factors, such as Rot 
(repressor of toxins), both of which are involved in cell signalling pathways which alter rate 
of spa gene transcription.170 Importantly,  spa gene transcription is inversely related to the 
activity of quorum-sensing transcriptional factors, such as agr.171 In the opposite 
relationship to secreted exotoxins, studies show a 25-fold increase in Protein A production 
displayed in mutated  agr-knockout cells.172 Furthermore, when RNA III expression is 
maximal, during the postexponential phase of bacterial growth, SpA production is inhibited 
(Figure 8).168 





Figure 8- Diagram describing the growth phases (x axis) of S. aureus to bacteria number (y axis), and type of 
virulence factor production. Adapted from Harris et al.12 
 
The control of virulence factor expression is related to the stages of S. aureus infection. In 
acute infection, with high bacterial cell density and greater nutritional need, agr promotes 
the release of toxins and digestive enzymes.171 In initial colonisation, or chronic, low-lying 
infection, the agr system is suppressed, which in turn promotes the expression of SpA and 
other surface proteins.173 This is evidence of a further adaptive response by S. aureus to its 
environment, in order to promote ongoing infection, as surface proteins are primarily 
involved in adherence to host tissues and biofilm formation. In the case of SpA, increased 
production during times of low bacterial load may correlate to its primary role in immune 
evasion, allowing S. aureus to survive as a commensal organism.144 
1.10 Processing and excretion of Protein A 
The excretion of SpA from the body is known to involve the formation and processing of 
SpA-IgG complexes; a study conducted using radio-labelled SpA-IgG complexes injected into 
rabbits showed maximal uptake of complexes by the liver and spleen.174 This indicates that 
SpA is first sequestered and metabolised by the body before excretion from the urine. 
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Studies into the processing and excretion of naturally occurring SpA, released into the body 
by infection with S. aureus, are rare in the literature, but the potential use of SpA as a 
therapeutic agent has provided animal and human pharmacokinetic studies. In a study of IV 
SpA administration in Cynomolgus monkeys showed that a weekly dosage of 100µg/kg SpA 
is non-toxic and well tolerated, and clearance of purified SpA from plasma is rapid following 
administration.175 Of particular note, the presence of anti-SpA antibodies was associated 
with quicker excretion, even after first dose, implying that there exists a pre-formed 
immune response in certain animals. 
Tests of SpA pharmacokinetics in human subjects are rare, however, following successful 
animal trials, the potential for immune modulation of SpA in autoimmune disease has 
prompted clinical trials. A Phase I human trial was undertaken in 2013, involving 20 healthy 
subjects given single doses of SpA, at either 0.3µg/kg and 0.45µg/kg.176 Generally, the doses 
were well tolerated by subjects, and complete clearance of SpA had occurred by 96 
hours.176 Immunological studies showed an anti-SpA antibody response in 63% of all 
subjects tested, and that antibody-positive patients showed increased frequency of SpA 
clearance. This provides further evidence that formation of anti-SpA antibodies is an 
important step in the excretion of SpA from the body, but not essential. This rapid clearance 
does not require sequestration and breakdown in the liver or spleen, as other 
Staphylococcal bacterial toxins found bound to antibodies in human serum, such as SEB, are 
cleared within 24 hours via the kidneys.177 Other animal studies have located an 
accumulation of Staphylococcal exotoxins TSST-1 and SEB in rat renal tissue, from inoculated 
burn sites, proving that the processing and excretion of toxins from primary infection sites 
involve the kidneys.178 Studies have yet to investigate whether SpA is found in the kidneys 
or urine during excretion, providing an area of opportunity for research. 
1.10.1 Detection of naturally occurring Protein A in human samples 
SpA has been used for the precipitation and purification of antibodies from serum, culture 
supernatants and other solutions, since its discovery, and this is usually achieved through 
the use of SpA-affinity columns.179, 180 Detection of SpA by immunoassay was first achieved 
in order to detect SpA contaminants from commercially sourced antibody products.181 
Optimisation of ELISA methods for detection of SpA in commercial antibody products has 
produced techniques capable of detecting 0.2ng/ml SpA,182 though despite this, attempts to 
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apply these tests to the detection of SpA in clinical samples are rare in the published 
literature. 
In 1991, Nilsson et al described an ELISA method for the detection of commercial SpA in 
human serum samples, which had so far not been accomplished.183 The main complication 
in detecting SpA in serum samples was the presence of IgG in serum; this was theorised to 
interfere with the immunoassay by competitively binding to SpA, and previous studies have 
demonstrated this effect by adding IgG to purified SpA samples, and producing a quenching 
effect on ELISA.184  Only after boiling SpA-spiked serum samples was detection possible, 
implying that IgG-SpA complexes in serum could be broken by boiling. Using this preparation 
method, detection was possible down to a level of 5ng/ml, compared to 0.5ng/ml in buffer, 
implying that sensitivity of SpA detection is still reduced in serum even after boiling samples.  
Endogenous SpA, produced during the course of natural S. aureus infection, has been 
detecting patient serum samples by ELISA. This was done by Steindl et al, using the method 
of boiling patient samples as outlined by Nilsson et al; boiling (and dilution) was again 
demonstrated to be the optimal method of preparing samples and dissociating SpA-
antibody complexes.185 Patients positive for SpA in this study were known to be infected 
with S. aureus, though the amount of SpA detected was small and varied between patients, 
from 0.25ng/ml to 7.9ng/ml.185 
A different method of SpA testing, the detection of host antibodies raised against SpA in 
serum, has also been achieved through ELISA. This was developed by Greenberg et al, using 
SpA as capture antigen and saturating Fc binding sites with human IgG Fc fragments, prior to 
incubation in human serum samples and final detection using an anti-IgG (Fab-region 
specific) antibody.186 Samples tested were from patients with confirmed S. aureus 
endocarditis, and results showed that the ELISA was able to distinguish between 
endocarditis patients and controls, but the test displayed a low sensitivity (52%) and 
specificity (48%) for distinguishing between the two groups. Further work into 
immunoassays for detecting antibody responses to SpA in human samples are currently 
lacking. 




Staphylococcus aureus is a Gram-positive bacterium capable of causing life-threatening 
infection in humans, and is aided by a wide range of virulence factors which directly damage 
the host, and evade host defences. Peptidoglycan-anchored surface proteins allow S. aureus 
to project virulence factors from the cell wall; the first discovered surface protein, SpA, can 
also be found free in culture medium. SpA has a number of functions, the most important of 
which is the ability to bind host antibodies by both the Fc and Fab regions, providing S. 
aureus with innate and adaptive immune system evasion.  
The detection of endogenous SpA in S. aureus infection has not been achieved in patient 
urine samples, though the detection of antibodies against SpA in human serum has been 
demonstrated. As such, the presence of SpA in human urine samples has not been assessed 
as a potential antigen test for S. aureus infection. 
The emergence, and continual adaptation of, antibiotic-resistant strains of S. aureus 
continues to make S. aureus infection a serious consequence of ICU admission. Correct and 
timely treatment with antibiotics is essential for a good outcome from S. aureus 
bloodstream infection, and blood-culture diagnosis of S. aureus infection can be a slow 
process. Rapid detection of bacterial infection through antigen testing has been previously 
achieved for other pathogens, and has allowed rapid detection of infection through non-
invasive means such as urine testing. Development of a sensitive and specific urinary 
antigen test for S. aureus, with SpA as the antigen, would allow optimal antibiotic treatment 
to commence sooner, improving the management of S. aureus infection. 
1.12 Aims 
This study aims to optimise and develop the work of Yue Han (MSc 2014),187 in detecting 
SpA in ICU patient urine samples by Western Blot methods. Other aims include the 
development of an enzyme-linked immunosorbent assay (ELISA), based on the methods 
established by Frances Price (MSc 2013),80 for the detection of commercial SpA and SpA in 
ICU patient urine. Mass Spectrometry will be utilized to detect SpA in any appropriately 
sized bands seen on SDS-PAGE gels, using a unique method for detecting S. aureus toxins by 
MS. The overall aim of this work is to assess the suitability of SpA as a urinary biomarker for 
S. aureus infection in ICU patients. 
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2 Materials and Methods 
2.1 Materials: 
2.1.1 Western Blot materials: 
2.1.1.1 Material for SDS-PAGE gels: 
 Mini-PROTEAN Tetra Cell Gel kits (BioRad- 165-8000) 
 Mini-PROTEAN Glass Plates (BioRad- 1653311) 
 Mini-PROTEAN Short Plates (BioRad- 1653308) 
 Criterion Blotter Transfer Packs (BioRad- 170-4070) 
 Acrylamide 30% Ultra-Pure Protogel (National Diagnostics- EC-890) 
 N’N’N’N’ Tetramethylethylenediamine (TEMED)- (Sigma- T9281) 
 Ammonium Persulphate (APS) powder (Sigma- A3678)  
 Sodium Dodecyl Sulphate (SDS) powder (Fisher Scientific- S/5200/53) 
 TRIS-Glycine-SDS PAGE buffer (Geneflow, Staffordshire, UK- B9-0034) 
2.1.1.2 Antigens 
 Protein A, purified from S. aureus cell culture (Sigma- P6031) 
 Alpha-haemolysin from S. aureus (Sigma- H9395) 
 Staphylococcal Enterotoxin B (SEB) from S. aureus (Toxin Technology- BT202red) 
 Toxic Shock Syndrome Toxin 1 (TSST-1) from S. aureus (Toxin Technology- TT606) 
 Immunoglobulin G from human serum (Sigma 56834) 
2.1.1.3 Antibodies: 
 Anti-Protein A antibody- polyclonal chicken IgY HRP-conjugated (Abcam- ab18596) 
 Anti-human IgG antibody- polyclonal rabbit IgG HRP-conjugated (Biotin- ab6758) 
2.1.1.4 Protein Standards for Western Blot 
 Protein Mixture ladder (GE Healthcare- 17044601) 
 Precision Plus Protein Dual Colour Standards (BioRad- 161-0374) 
 Kaleidoscope Prestained Standards (BioRad- 161-0324) 
SID: 33007675                                                                                                                        Christopher Varley 
41 
 
2.1.1.5 Washing and blocking materials: 
 Phosphate-Buffered Saline Tablets (Sigma- P4417- 100 tablets) 
 TWEEN® 20 (Sigma-Aldrich- P1379 500ml) 
 Milk- dried milk powder (Marvel original) 
 Bovine Serum Albumin, lyophilized powder (Sigma- A7906) 
2.1.1.6 ECL Substrate: 
 P-Coumaric Acid powder (Sigma- C9008).  
 Luminol powder (Sigma- A8511).  
2.1.1.7 Membranes: 
 Immobilin-P PVDF Membranes (Merck- PHV00010) 
2.1.2 Mass Spectrometry Materials: 
2.1.2.1  Sample preparation: 
 Acetonitrile (Sigma- 494445) 
 Dithiothreitol (DTT)- (Melford- MB1015) 
 Trypsin Singles Proteonomics Grade (Sigma- T7200) 
 Trypsin Reaction Buffer (Sigma- R3527) 
 Trypsin Solubilising Agent (SigmaT2073) 
 Coomassie Brilliant Blue R (powder)- (Thermo-Fischer Scientific- 20278) 
2.1.2.2 ELISA Materials: 
 TMB Microwell Peroxidase Substrate- SureBlueTM Reserve (KPL-  53-00-00) 
 Human serum from male AB plasma (Sigma- H4522- 20ml) 
 Gelatine, from cold water fish (Sigma- G7765- 250ml) 
 Carbonate-Bicarbonate capsules (Sigma- C3041- 100 capsules) 
2.1.2.3 Bradford Assay Materials: 
 Brilliant Blue Protein Reagent (Sigma- B5809- 100ml) 
 





2.2.1 Western Blot for Protein A samples in control and sample urine 
2.2.1.1 Making polyacrylamide gels for SDS-PAGE electrophoresis 
Initially, front and backing gel plates were fixed with plastic gel holders, with 1mm space 
between. Acrylamide gels were prepared separately as stacking and resolving gels, with 
varying amounts of acrylamide. A solution of 12% acrylamide resolving gel (6.3ml dH20, 5ml 
1.5M Tris HCl pH8.8, 8.3ml 30% (w/v) acrylamide, 200µl 10% (w/v) APS, 200µl 10% (w/v) 
SDS and 20µl TEMED- sufficient for 4 gels) was prepared in a test tube and pipetted into the 
space between the Mini-PROTEAN glass and short gel plates, leaving a 2cm space at the top. 
A small amount of isopropanol was pipetted onto the top of the resolving gel to remove 
bubbles. After allowing 30 minutes for the gel to set, the isopropanol was washed off with 
dH20. Stacking gel (7.66ml dH20, 1.26ml 1M Tris HCl pH 6.8, 1ml 30% (w/v) acrylamide, 
0.5ml 10% (w/v) APS, 100µl 10% (w/v) SDS and 10µl TEMED- sufficient for 4 gels) was then 
pipetted in the remaining space to the top of the front gel plate. A 10-well comb was then 
immediately placed into the gel, and the combined gels were allowed to set for 30 minutes. 
2.2.1.2 Preparing and loading samples 
Included in Western Blots was a protein mixture used as a molecular weight protein ladder 
(see materials). SpA samples were prepared (1mg/ml) in either boiled control urine or 
Phosphate Buffered Saline (PBS), and dilutions for analysis prepared from that stock. Patient 
urine samples were defrosted, and then vortexed and warmed at 360Cto reconstitute any 
material in the sample which had fallen out of solution. In general, all samples and controls 
were mixed with loading buffer (1.15M TRIS, 10% (w/v) SDS, 0.08M DTT, 20% (v/v) glycerol, 
2.5% (w/v) bromophenol blue in 25ml total volume of dH2O) at a ratio of 2/3 sample and 
1/3 loading buffer. In the case of a sample being only used to load a single well, this used 
8µl of sample and 4µl of loading buffer. Samples mixed with LB were vortexed and heated 
at 980C for 3 minutes. Following this, they were centrifuged for 1 minute in a bench-top 
centrifuge at 10,000g, to collect any sample which may have been present on the sides and 
lid of the microfuge tubes.  
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To load the gels, firstly the 10-well comb was removed from the stacking gel, and the 
combined plates were fitted into the Mini-PROTEAN Tetra cell system and then placed in the 
running tank. Tris-Glycine-SDS PAGE buffer was poured into the central reservoir and 
allowed to fill the wells. An aliquot 10µl of each sample was pipetted into each well. 
Once loaded, the surrounding tank was filled with Tris-Glycine-SDS PAGE buffer, and 
electrophoresis performed at 140v for 1.5 hours. Following this, the gels were removed 
from the glass plates ready for transfer. 
2.2.1.3 Transferring to Polyvinylidene fluoride (PVDF) membrane 
The gels were transferred using the ‘wet’ transfer method, using membranes and filter 
papers soaked in transfer buffer (20mM Tris, 150mM Glycine and 20% methanol). First, 
PVDF membranes (Immobilion P, Millipore, UK) were cut to a size of 6cm x 9cm, then 
equalised by placing in pure methanol for 10 seconds, dH20 for 2 minutes and finally 
transfer buffer for at least 20 minutes. The Criterion transfer pack was formed as a 
‘sandwich’ made by stacking the following layers from bottom to top; 4 pieces of filter 
paper, gel, PVDF membrane and finally 4 more pieces of filter paper. The transfer packs 
were closed and put into a tank of transfer buffer, with an ice pack and magnetic stirrer, in 
order to keep the gels cool during the transfer period. An electric current (115v/700mA) was 
then passed from the back to the front of the tank, for 1.5 hours. 
2.2.1.4 Washing and blocking 
Following transfer, the membranes were removed from the transfer pack and placed in PBS- 
0.1% (v/v) Tween 20 (PBST), and washed on the rotary agitator at RT for 1 minute. Following 
this, the PBST was removed and 20ml of blocking buffer was applied; blocks used were 5% 
(w/v) skimmed milk, 2% (w/v) BSA or 5% (w/v) BSA. Membranes were incubated in the 
selected blocking solution on a rotary agitator overnight in a cold room, or for 1 hour at RT. 
2.2.1.5 Incubation in antibody 
The blocking solution was removed and the membranes were washed with PBS- 0.1% (w/v) 
Tween 20 for 1 minute, then twice more, each for a further 15 minutes. A solution of 
primary antibody was diluted in either 20ml 5% (w/v) milk or 2% (w/v) BSA, and applied to 
the membranes.  Antibody concentrations used ranged from 1:500 to 1:10000. The 
membranes were incubated in primary antibody for 1.5 hours on a rotary agitator at RT. 
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2.2.1.6 Washing and Western Blot image development 
Following incubation in primary antibody, the antibody solution was poured off and the 
membranes were washed in PBST, 3 times, for 15 minutes each. This allows final removal of 
non-specific or HRP-conjugated antibody displaying on development of the image. Electro-
chemiluminescence substrate (ECL), comprising 1M Tris HCl pH 8.0 solution, Luminol and p-
Coumaric acid (see materials), was prepared immediately prior to use, and 2-3ml was 
applied to each membrane. Following incubation for 1 minute, they were placed on a piece 
of transparent film and images were saved on a Chemidoc image reader (BioRad), using the 
software Image Lab (BioRad). 
After viewing, membranes were transferred to a separate plate for staining with amido 
black (125ml dH20, 100ml methanol, 25ml glacial acetic acid and 0.1% (w/v) Amido 
Black)solution, which was applied for 3 minutes at RT. They were then washed in de-stain 
solution (50% (v/v) dH20, 40% (v/v)methanol and 10% (v/v) glacial acetic acid) 3 times, for 
15-20 minutes, to allow for optimal viewing of bands. They were then photographed by the 
Chemidoc, using Brightfield settings within the Image Lab software. 
2.2.2 Mass Spectrometry 
2.2.2.1 SDS-PAGE gel electrophoresis and gel staining 
Samples to be examined were subject to polyacrylamide gel electrophoresis, prepared as 
described above. Samples were prepared in the same 1/3rd ratio of loading buffer to sample, 
as described above for WB sample preparation, and 10µl of each were loaded in a 10-well 
gel and electrophoresis was performed for 1.5 hours at 140v. Following this, the gels were 
placed in 10ml of Brilliant BlueTM Coomassie Stain (50% dH20, 40% methanol, 10% glacial 
acetic acid and 0.25% (w/v) Coomassie Brilliant BlueTM), for 1 hour or overnight, on an 
orbital mixer. 
 
Following staining, the gels were washed for 10 minutes in destain solution (described 
above), and fresh destain was added every hour for 3-4 hours. The gels were rehydrated in 
20ml of dH20 overnight. 
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2.2.2.2 Sample Preparation 
The gels were transferred to transparent PVC, where the regions to be prepared for analysis 
by Mass Spectrometry were identified. Prior to sample preparation, the gels were viewed 
and digital images captured saved using a Chemidoc, on the Coomassie Blue setting within 
the Image Lab software. 
The chosen regions were cut out of the gel using a clean scalpel, and then divided into 1mm 
by 1mm squares. These were placed into clean Eppendorf microfuge tubes and centrifuged 
for 10 seconds to ensure their placement at the bottom of the microfuge tube. Then 150µl 
of Acetonitrile (ACN) was added to each sample, and they were incubated at RT for 30 
minutes, with occasional vortexing. Once the gel pieces had shrunk, the ACN was removed, 
and 50µl of DTT solution (1M DTT in 990µl of 100Mm Ammonium Bicarbonate (ABC) pH 8.5 
solution) was added to the gel pieces. The samples were incubated in DTT at 560C for 30 
minutes. Following this, the DTT solution was removed, 150µl of ACN was reapplied to the 
gel pieces and they were incubated at RT for 30 minutes. 
The ACN was then removed and 50µl of Iodoacetamide (10mg of Iodoacetamide in 100µl of 
ABC) was applied to each sample and the gel pieces kept at RT and in a dark environment 
for 20 minutes. The Iodoacetamide was removed and a further 150µl of ACN reapplied for 
30 minutes at RT.  
2.2.2.3 Trypsin Digestion 
Trypsin was prepared by adding 45ul of trypsin reaction buffer and 5ul of trypsin solubilising 
agent to each trypsin vial. Following removal of the ACN from each sample, 25µl of this 
trypsin mixture was added, briefly mixed and kept at 40C for 30 minutes. Following this, a 
further 30µl of trypsin reaction buffer was added to each sample, briefly mixed and then 
incubated overnight (minimum 18 hours) in a 370C incubator. 
Following overnight trypsin digestion, the trypsin was removed by pipette, and the peptides 
were extracted from the gel pieces with 110µl of extraction buffer (1:2 mixture of 5% Formic 
Acid and ACN). These were incubated at 370C for 20 minutes, before the extract was 
transferred to fresh microfuge tubes, with 4 holes cut into the lid. These were placed into a 
freeze-dryer, and set at a cycle of 1 hour freezing, 16 hours of drying and 1 hour final drying. 
The resulting samples were stored at -200C until use. 
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2.2.2.4 LC-MS Sample Processing 
Freeze-dried samples were reconstituted with 20µl of 0.1% trifluoroacetic acid (TFA), before 
being placed in an ultra-sonicating bath for 5 minutes and centrifuged for 1 minute. Then, 
20µl of reconstituted sample was transferred to micro-vials and placed within the Ultimate 
3000 (LC PackingsTM a Dionex
TM Company) autosampler trays. Prior to sample acquisition, 
the computer software Esquire ControlTM  and Chromeleon ExpressTM were used to calibrate 
liquid chromatography settings, to a loading flow of 0.25µl/s and a voltage of ~150v. Sample 
was subject to ionising spray, followed by mass spectrometry analysis, for 110 minutes. 
Following acquisition of data, these data were analysed using the programmes Bruker 
DaltronicsTM and BiotoolsTM software, followed by hit searches using the online MascotTM 
tool. Online search parameters were used to restrict results to Eurkaryotic bacteria in 
certain searches. 
2.2.3 Enzyme-linked immunosorbent assay (ELISA) for the detection of Protein A 
in urine samples 
 
An ELISA method was initially developed by Harrison et al for the detection of 
Staphylococcal exotoxin in infant urine samples,79 and further optimised by Frances Price 
(MSc 2013),80 for the detection of exotoxin in the same urine samples which are the subject 
of investigation in this study. Initial development of a sandwich ELISA for the detection of 
SpA was based on these methods, using IgG as a capture antibody. 
Microwell plates (Nunc-Immuno F96 Maxisorp, Thermo Scientific, Hemel Hempstead, UK) 
were coated with 0.5µg/ml IgG in coating buffer (0.1M carbonate-bicarbonate, pH 9.6, 
Sigma-Aldrich) , at a volume of 100µl per well. Plates were incubated in IgG overnight, at 
40C. 
The following morning, plates were emptied and washed four times with 200µl/well PBS-
0.05% (v/v) Tween 20, using a multi-channel pipette. Following each wash the wells were 
emptied by inverting the plates directly and tapping downward on blue roll. Following this, 
200µl/well 5% (w/v) milk or 2.5% (w/v) fish gelatine was added to the plates and incubated 
for 1 hour at 370C. 
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Following the blocking stage, plates were washed, as described above. SpA standards, in 
either PBS or control urine, and patient samples were then added to the plate, 100µl/well, 
and plates were incubated for 1 hour at 370C. 
Following another wash phase, 100µl of polyclonal chicken IgY anti-SpA antibody, 1:4000 or 
1:8000 in blocking buffer, were added to each well and the plates incubated for 1 hour at 
370C, then washed as previously described. 
To develop the plates, 100µl of substrate (TMB Microwell Peroxidase, KPL, Gaithersburg, 
MD) was added to each well, and the reaction allowed to proceed for 10 minutes, before 
being stopped by the addition of 100µl/well of stopping solution (0.3M H2SO4).  
The absorbance of each well was measured at 450nm, using a Wallace Victor Plate Reader 
(Perkin Elmer, Buckinghamshire, UK).  
2.2.4 Protein Assay for total protein estimation in patient urine samples 
2.2.4.1 Preparing protein standards 
Total protein was measured in patient samples using an assay measuring the absorbance of 
samples following application of a Coomassie Brilliant Blue assay solution, as compared to a 
blank standard. A blank standard was produced by adding 50µl of NaCl solution to 2.5ml of 
Protein Assay Standard (PAS). The blank was measured for absorbance by placing 1ml of the 
standard in a cuvette and measured at 595nm using an EppendorfTM BioPhotometer. This 
produced a calibrated absorbance of 0.000. A standard solution of 300mg/ml BSA was 
prepared in dH20. A Protein Assay Solution (PAS) was made by combining Coomassie 
Brilliant Blue R with dH20 in a mixture of 1 to 4. A volume of 50µl of 300mg/ml BSA solution 
was added to 2.5ml PAS, to give a final concentration of 6mg/ml, and left to react for 2 
minutes. A volume of 1.25ml of this solution was added to 1.25ml of fresh PAS, in order to 
divide the protein concentration by half. This solution was again left for 2 minutes. This 
process was repeated 12 times in order to generate a protein curve down to a 
concentration of 0.073mg/ml. These standards where then measured in the same way as 
the blank, in order to produce a curve. 
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2.2.4.2 Testing patient samples for total protein 
Once the protein curve was established, patient samples were created by adding 50µl of 
undiluted patient sample to 2.5ml of PAS. This was left to stand for 2 minutes and measured 
in the same way as the standard protein samples. 
2.3 Patient sample collection and characteristics 
Patient samples from 47 patients were collected from the Lancaster Royal Infirmary ICU 
ward, by a previous MSc student,80 in 2012-2013, over an inpatient period of at least 48 
hours. Aims of collection were to acquire 8 samples per patient, at intervals of 4 hours, 
giving a full inpatient sample range. The average sample number per patient was 7, with 
some patients providing less than the required number. This was due to a failure to collect 
urine, lack of urine production by the patient, or death of the patient during admission. 
Samples were collected from the patient catheter port, and placed immediately into sterile 
containers at 40C. They were then stored at -800C, until use.  
With each patient sample range, demographic, clinical and biochemical data were collected 
into a database. Patient age and diagnosis at admission and prognosis (death during 
admission) are summarised in the appendix. 
2.3.1 Statistical Analysis 
Statistical analysis, based upon the findings of this primary research and the pre-existing 
clinical database, was performed with the statistical program Stata (Edition 12- StataCorp). 
The statistical tests performed on these data comprised of: 
 Student’s T-test- for continuous data 
 Logistic regression- for categorical data 
2.4 Ethical Approval 
This study received a favourable opinion from Greater Manchester South Ethics Committee, 
with reference: 12/NW/0783. 
An amendment to the above approval was required to allow research to be carried out by 
successive students on patient urine samples; amendment reference number 12/NW/0136, 
amendment number 2. 




3.1 Method Development- Western Blot for commercial Protein A 
Initial method development focused on the detection of commercial SpA by Western Blot 
(WB), using primary HRP-conjugated anti-SpA antibody. The basis for the WB technique was 
that developed for the detection of S. aureus exotoxin by Frances et al, which was to use 
SDS-PAGE electrophoresis to separate the proteins in patient urine samples and probe with 
toxin specific antibody.80 To ensure the positive identification of SpA, the WB method would 
first have to be capable of detecting small amounts of the target protein in standard 
samples. The detection of commercially purified SpA by WB had previously been performed 
by Yue Han (MSc 2014),187 however, that work achieved this by using high amounts of 
antibody which proved to be highly sensitive for SpA, but displayed high background. The 
initial aim of our WB method development was to ensure that the test was both sensitive 
and specific for biologically relevant levels of SpA, to measure and confirm the standard MW 
of commercial SpA, and to determine the ideal antibody concentration and blocking 
solutions for testing patient samples for endogenous SpA. 
3.1.1 Western Blot to detect commercial SpA in PBS and control urine 
The detection of commercial SpA by WB was confirmed in control urine, at concentrations 
starting at 10µg/ml, and decreasing by 10 times dilution to 0.001µg/ml (Figure 10--13). 
Primary antibody was used at high concentrations (1:500 and 1:1000), and suspended in 
both 5% (w/v) milk and 2% (w/v) BSA. These concentrations of antibody were those used by 
Yue Han (MSc 2014) in the screening of patient samples for SpA, so were seen as an 
appropriate baseline for WB detection (Figure 9-12).187 
 
 




Figure 9- Western Blot of SpA controls of varying concentrations constituted in control urine, using a 1:500 
concentration anti-SpA antibody constituted in 5% (w/v) milk.  Standards of SpA are electrophoresed on SDS-
PAGE gel, before being transferred to membrane as per protocol. Membrane blocked in 5% (w/v) milk, and 
incubated in 1:500 concentration of anti-SpA antibody, constituted in 5% (w/v) milk. Ladder proteins are not 
visible. 
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Figure 10- Western Blot of SpA controls of varying concentrations constituted in control urine, using a 1:1000 
concentration anti-SpA antibody constituted in 5% (w/v) milk. Standards of SpA are electrophoresed on SDS-
PAGE gel, before being transferred to membrane as per protocol. Membrane blocked in 5% (w/v) milk, and 
incubated in 1:1000 concentration of anti-SpA antibody, constituted in 5% (w/v) milk. Ladder proteins are not 
visible. 
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Figure 11- Western Blot of SpA controls of varying concentrations constituted in control urine, using a 1:500 
concentration anti-SpA antibody constituted in 2% (w/v) BSA. Standards of SpA are electrophoresed on SDS-
PAGE gel, before being transferred to membrane as per protocol. Membrane blocked in 2% (w/v) BSA, and 
incubated in 1:500 concentration of anti-SpA antibody, constituted in 2% (w/v) BSA. 
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Figure 12- Western Blot of SpA controls of varying concentrations constituted in control urine, using a 1:1000 
concentration anti-SpA antibody constituted in 2% (w/v) BSA. Standards of SpA are electrophoresed on SDS-
PAGE gel, before being transferred to membrane as per protocol. Membrane blocked in 2% (w/v) BSA, and 
incubated in 1:1000 concentration of anti-SpA antibody, constituted in 2% (w/v) BSA. 
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These initial WBs resulted in a clear and strongly positive detection of SpA at 10µg/ml, 
1µg/ml and 0.1µg/ml, with faint and variable detection of a band in the 0.01µg/ml lane. All 
of these bands were produced from SpA diluted in control urine, confirming the viability of 
SpA detection in the matrix under investigation in this research.  
However, as each of these samples are further diluted by preparation of a 1/3 loading buffer 
sample at 10µl per well, these initial concentrations are equivalent to approximately 70ng, 
7ng and 0.7µg total volume of SpA in each lane. The definitive detection limit was therefore 
the lowest possible amount detectable by this method under optimal conditions, which was 
0.7ng. However, it was recognised that the signal was weak for this amount of SpA, 
especially at lower antibody concentration, and that the likely condition of patient urine 
samples did not represent ideal testing conditions for WB. As a 0.01µg/ml SpA solution 
could not be relied upon as a reliable standard during sample testing, the decision was 
made to utilise commercial SpA in standards at a concentration of 0.1µg/ml (70ng total 
SpA). 
 Healthy control urine, without added SpA, was found to have no positive bands detected by 
the antibody, proving its suitability as a control lane substance in WB experiments.  
At this initial phase, unwanted background and non-specific signal was found to be more 
effectively diminished by blocking, and incubating antibody, in 2% (w/v) BSA.  
Following this,  a series of experiments were carried out, which tested the detection limit of 
the primary anti-SpA antibody, by reducing the concentration for primary antibody to 
1:8000, and incubating a serial dilution of SpA in this concentration of antibody (Figure 13). 
Also included with each WB was a mixture of protein standards (ladder) to provide the MW 









Figure 13- Western Blot of SpA standards constituted in control urine, detected by 1:8000 anti-SpA antibody 
concentration. Standards were constituted at varied concentrations in control urine, before being loaded into 
SDS-PAGE gels and being subject to electrophoresis and transferred to membrane as per protocol. Membranes 
were blocked in 2% (w/v) BSA and then incubated in 1:8000 anti-SpA antibody in 2% (w/v) BSA. 
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Detection of SpA was found to be possible using lower antibody concentrations, down to 
1:8000, to reveal the SpA from a 0.1µg/ml solution. This level of detection was achieved in 
control urine, showing this method was appropriate for the medium in which we were 
aiming to detect endogenous SpA. Detection of SpA concentrations of 0.01µg/ml or below 
was only seen when using 1:500 antibody concentration, amounts which caused 
considerable background and bleaching of patient sample lanes when used by Yue Han (MSc 
2014) on patient samples.187 It was therefore decided that the reliable detection of SpA in 
0.1µg/ml solutions, or total SpA of 7ng per sample well, with the lowest concentration of 
anti-SpA antibody, would be the main outcome of optimising the WB method.  
Additional information provided by these blots were the MW of commercial SpA and the 
appearance of SpA when electrophoresed on SDS-PAGE gels. The MW of SpA was estimated 
using the BioTools Image Lab software, using protein standards of known weight in order to 
calculate the estimated MW of SpA bands detected.  The MW of SpA was consistent 
between blots, and was found to run at 50-55 kDa, as opposed to its documented MW of 
42kDa, a figure which was provided from the product information . However, this MW is 
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measured from the Cowen I strain of S. aureus, and SpA from different strains display 
heterogeneity.114 Our findings are consistent with findings on Western Blots by other 
studies using SpA from S. aureus strain 8325, the strain cultured to obtain the purified SpA 
used in this study.114, 117 This MW is evident in the following Western Blot (Figure 14): 
 
Figure 14- Western Blot- Protein Standards ladder, tested with 0.1µg/ml (7ng total volume) SpA standards. The 
prepared samples were loaded into SDS-PAGE gel, and electrophoresed and transferred to membrane as per 
protocol. Membranes were blocked in 2% (w/v) BSA, and incubated in 1:2000 anti-SpA antibody in 2% (w/v) 




Band 1 54.8 
Band 2 51.1 
  
On the WB, SpA consistently displayed the appearance of 2 close bands at the position of 
~50-55 kDa. These bands are of similar MW, the higher band appearing to run to ~55kDa 
and the lower band to 50kDa, and show similar signal strength (a slightly stronger signal on 
the heavier band was noted in certain experiments). This indicates that both molecules 
which produce the bands are of similar size and relatively at the same concentration in the 
commercial SpA standards. At concentrations of 1µg/ml and above, these SpA double bands 
merge into a single large band. Work by Yue Han (MSc 2014), which used mass 
spectrometry (MS) to examine samples from the 2 gel bands stained with Coomassie Blue, 
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found that both these bands match the molecular structure of SpA.187 It is very likely 
therefore, that these bands both represent variants of SpA at different MWs, though the 
reason for the resolution of two differently sized SpA molecules within a commercially 
produced sample was unknown. 
Based on these initial experiments on SpA in control urine, it was revealed that the chosen 
lowest reliable concentration of SpA, 0.1µg/ml was visualised well at antibody 
concentrations 1:1000 and 1:2000, and provides a clear view of the SpA double bands 
without bleaching adjacent lanes (see Figure 15). 
 
Figure 15- Western Blot of SpA standards, constituted in control urine, and incubated in different antibody 
concentrations. SpA standards were constituted at a variety of concentrations. The prepared samples were 
loaded into SDS-PAGE gel, and electrophoresed and transferred to membrane as per protocol. Membranes 
were blocked in 2% (w/v) BSA, and incubated in 1:1000 concentration anti-SpA antibody (A), and 1:2000 
concentration anti-SpA antibody (B). Both antibody concentrations were constituted in 2% (w/v) BSA.   
 
Lane 1 2 3 4 5 
Sample Ladder Control Urine 0.1µg/ml SpA   0.01µg/ml SpA   0.001µg/ml 
SpA 
 
The reliable detection of SpA in control urine samples, when spiked with commercial SpA to 
a concentration of 0.1µg/ml, was demonstrated. An additional series of blots were done to 
demonstrate this in both healthy control urine and a sample of ICU patient urine, to a level 
of 0.1µg/ml and 0.01µg/ml SpA (Figure 16 and 17): 




Figure 16- Western Blot of SpA standards (0.1µg/ml - 0.01µg/ml concentration, total volume 7ng – 0.7ng) in 
control urine and patient urine (Patient 18, sample number 5). Samples were loaded into SDS-PAGE gel, and 
electrophoresed and transferred to membrane as per protocol. Membranes were blocked in 5% (w/v) milk, 
and incubated in 1:4000 anti-SpA antibody in 5% (w/v) milk. 
 
 
Figure 17- Western Blot of SpA standards (0.1µg/ml - 0.01µg/ml concentration, total volume 7ng – 0.7ng) in 
control urine and patient urine (Patient 18, sample number 5). Samples were loaded into SDS-PAGE gel, and 
electrophoresed and transferred to membrane as per protocol. Membranes were blocked in 5% (w/v) milk, 
and incubated in 1:8000 anti-SpA antibody in 5% (w/v) milk. 
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Following these experiments to assess the limits of sensitivity for the anti-SpA antibody, a 
WB experiment was performed to investigate the specificity of the anti-SpA antibody in 
relation to previously tested S. aureus toxins by this laboratory.80 This experiment tested for 
SpA, SEB, TSST and AH to a standard sample concentration of 1µg/ml, incubated in 1:1000 
and 1:2000 anti-SpA antibody. These standards concentrations of Staphylococcal toxins 
Lane 1 2 3 4 5 
Sample 0.1µg/ml SpA  
(control urine) 
0.01µg/ml SpA  
(control urine)       
0.1µg/ml SpA   
(Patient 18 urine) 
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(patient 18 urine) 
Patient 18 urine (no 
SpA) 
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were based on standard solutions used by Frances Price (MSc 2013),80 and are significantly 
higher than the concentrations of toxin found in patient urine in the same research. The 
antigens were also made in 2 different solutions, PBS and control urine, to find out if the 
solutions exhibited any differences in SpA signal strength. The subsequent WB shows no 
cross-reactivity with SEB, TSST and AH at the same concentrations of SpA. SpA at 1µg/ml 
also shows evidence of attenuated signal when diluted in control urine (Figure 18). 
 
Figure 18- Western Blot of PBS and control urine standards containing SpA, SEB, TSST and AH. Each toxin was 
prepared in solution to a concentration of 1µg/ml (total volume 70ng). Each prepared sample was loaded into 
SDS-PAGE gel, and electrophoresed and transferred to membrane as per protocol. Membranes were blocked 
in 2% (w/v) BSA, and incubated in 1:2000 anti-SpA antibody in 2% (w/v) BSA. 
 





















The additional finding of this experiment, that the 1µg/ml concentration SpA  shows 
evidence of signal attenuation when detected in control urine and not PBS, prompted 
further experiments to investigate this finding. This was repeated when 0.1µg/ml SpA was 
made with PBS and a variety of healthy control urines, and re-examined together on the 
same gel. WB techniques also display an increased sensitivity for SPA when it is diluted in 
PBS, as is shown by the detection of 0.01µg/ml SpA in PBS, but not control urine. These 
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effects can be seen on the following WB, which utilizes 3 different healthy control urine 
samples in comparison to PBS samples (Figure 19): 
 
Figure 19- Western Blot of SpA standards prepared with PBS or healthy control urine, loaded intermittently. 
Each prepared sample was loaded into SDS-PAGE gel, and electrophoresed and transferred to membrane as 
per protocol. Membranes were blocked in 5% (w/v) milk, and incubated in 1:2000 anti-SpA antibody in 5% 
(w/v) milk. 
 




















(PBS)    
0.01µg/m
l SpA (CU 
1) 
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This blot also demonstrates an increased sensitivity by WB for SpA when made in PBS 
solution; the final three wells contain 0.01µg/ml SpA, wells 8 and 9 contained this amount in 
control urine and the final well, which contains a faint double-band, the SpA standard was 
constituted PBS solution. It was decided to investigate this effect further prior to completing 
WB method optimisation, in order to determine if the same effect would occur in patient 
urine samples. 
The attenuation of commercial SpA detection appeared to be specific to control urine. IgG is 
one component known to be present in urine, including healthy samples. Therefore, its 
strong binding to SpA was hypothesised to be disrupting either the sample preparation, or 
the binding of anti-SpA in the antibody incubation phase of WB. To test the IgG hypothesis 
in disrupting commercial SpA detection via WB, an experiment was set up which used only 
PBS as sample solution, with samples containing SpA alone, and SpA with added human IgG 
(Figure 20). 




Figure 20- Western Blot of SpA standards in PBS solution, spiked intermittently with Human IgG 10µg/ml. Each 
prepared sample was loaded into SDS-PAGE gel, and electrophoresed and transferred to membrane as per 
protocol. Membranes were blocked in 5% (w/v) milk, and incubated in 1:2000 anti-SpA antibody in 5% (w/v) 




This experiment demonstrates a lack of binding between IgG and anti-SpA antibody, as 
there are no positive bands seen on WB in the 10µg/ml IgG concentration lane. It also 
demonstrates a lack of association between signal strength of SpA and IgG contained within 
the sample solution. To test this theory further, it was decided that prior to WB experiments 
in patient urine, the control urine and patient urine should be tested directly for human IgG, 
using WB and incubating in anti-human IgG antibody. The resulting experiment confirmed 
the fact that both control and patient urine contains IgG, present on WB as heavy and light 
chains (see text below for approximate MW) (Figure 21). 
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0.1µg/










Figure 21- Western Blot of control urine and patient urine samples, identifying IgG with anti-human IgG 
antibody. IgG spiked standards, control and patient urine samples were prepared and loaded into SDS-PAGE 
gel, and electrophoresed and transferred to membrane as per protocol. Membranes were blocked in 2% (w/v) 
BSA, and incubated in 1:4000 anti-human IgG antibody in 2% (w/v) BSA. 
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This result is a clear indicator to the large amounts of IgG in patient urine samples, and even 
small amounts in healthy urine. These correlate to the correct MW as described for human 
IgG; IgG light chains (F) are ~25kDa, heavy chains (H) are ~50kDa, making a full molecule 
weight of ~100kDa.188 As was previously demonstrated, SpA binding in WB is not impaired in 
patient samples, including the samples used in Figure 14. This is further evidence that the 
presence of IgG in patient samples does not attenuate the signal of SpA when it is added to 
those samples and detected by WB. As attenuation did not appear to occur in the testing 
matrix under investigation (only control urine) this effect was not investigated further, 
allowing application of the method to patient samples. 
3.1.2 Optimising Western Blotting for detection of SpA in patient samples 
Following this period of optimising for the detection of commercial SpA by WB, it was 
decided to further optimise the method, based on the presence of multiple, strong bands 
seen in patient samples when tested previously by Yue Han (MSc 2014). While we had 
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determined the optimal antibody concentration to be 1:2000 for detecting commercial SpA, 
an initial experiment was performed to demonstrate the effect of differences in the primary 
antibody concentration on patient samples. Of the 45 patients who provided urine samples, 
we tested the first 5 patients, selecting a sample from the middle of their inpatient period, 
using primary antibody at a range of concentrations, from 1:1000 to 1:8000, diluted in 2% 
(w/v) BSA.  
A single sample from the middle of each patient series was tested due to previous data by 
Frances Price (MSc 2013) demonstrating that the middle sample of a series contained higher 
levels of Staphylococcal toxins. Included in sample testing were SpA standards diluted in 
both PBS and control urine, due to the potential, recognised, difference in signal strength 
which may occur in WB. The following series of blots demonstrates the detection of both 
SpA standards and multiple bands of higher and lower molecular weight and intensity in 











Figure 22- Western Blot of patient 1 – 5 urine samples, undiluted, with 0.1µg/ml SpA (total volume 7ng) 
standards, tested by 1:1000 concentration of antibody.  Included in Western Blot was a protein mixture as MW 
ladder. Patient samples and standards were electrophoresed in an SDS-PAGE gel and transferred to membrane 
as per protocol. Membrane was blocked in 2% (w/v) BSA and incubated in 1:1000 concentration anti-SpA 
antibody, also constituted in 2% (w/v) BSA. 
 
 
Figure 23- Western Blot of patient 1 – 5 urine samples, undiluted, with 0.1µg/ml SpA (total volume 7ng) 
standards, tested by 1:2000 concentration of antibody. Included in Western Blot was a protein mixture as MW 
ladder. Patient samples and standards were electrophoresed in an SDS-PAGE gel and transferred to membrane 
as per protocol. Membrane was blocked in 2% (w/v) BSA and incubated in 1:2000 concentration anti-SpA 
antibody, also constituted in 2% (w/v) BSA. 
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Figure 24- Western Blot of patient 1 – 5 urine samples, undiluted, with 0.1µg/ml SpA (total volume 7ng) 
standards, tested by 1:4000 concentration of antibody.  Included in Western Blot was a protein mixture as MW 
ladder. Patient samples and standards were electrophoresed in an SDS-PAGE gel and transferred to membrane 
as per protocol. Membrane was blocked in 2% (w/v) BSA and incubated in 1:4000 concentration anti-SpA 
antibody, also constituted in 2% (w/v) BSA. 
 
Figure 25- Western Blot of patient 1 – 5 urine samples, undiluted, with 0.1µg/ml SpA (total volume 7ng) 
standards, tested by 1:8000 concentration of antibody. Included in Western Blot was a protein mixture as MW 
ladder. Patient samples and standards were electrophoresed in an SDS-PAGE gel and transferred to membrane 
as per protocol. Membrane was blocked in 2% (w/v) BSA and incubated in 1:8000 concentration anti-SpA 
antibody, also constituted in 2% (w/v) BSA. 
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 This series of WB results show that the patient urine samples display a variety of bands, of 
different molecular weights, and of varying intensity. This can be clearly seen in patient 4, 
sample 5, with particularly strong bands seen in patient urine at ~60kDa and ~30kDa. 
Initially, it was thought that these bands may either entirely be due to non-specific binding, 
i.e. urinary proteins such as albumin exhibiting cross-reactivity with anti-SpA antibodies, or 
they are variants of SpA at different MWs. A mixture of SpA and non-specific binding was 
thought to be responsible for the large number of bands seen, so further optimisation work 
was carried out in order to reduce any non-specific binding on urinary proteins. 
The fainter of these additional patient bands are seen to disappear at lower antibody 
concentrations, as well as lower band intensity for SpA standards, which is to be expected. 
Following this series of blots, 1:2000 was decided as the most appropriate concentration of 
antibody for reducing the amount of non-specific binding, while also retaining a strong 
signal for SpA standards in PBS and control urine.  
Sample testing optimisation was continued by diluting patient samples; specifically, to 
examine whether the dilution of patient urine would reduce the number of additional bands 
seen on WB, while retaining binding to any endogenous SpA, and so allowing detection, in 
those samples. Patient samples were loaded undiluted and also diluted with PBS 2, 10, 20 
and 100 times. Patients 4, 30 and 33 samples were chosen as the sample volumes 
associated with these patients were amongst the largest in the series, allowing large 
amounts of urine to be used during a dilution. Also, patient 4 had previously demonstrated 
many strong additional bands in WB experiments and so would provide insight into the 
impact of this approach on the most challenging of patient samples. The subsequent WB 
results demonstrated significant attenuation in patient band signal when diluted 10 times 
(Figure 26 - 28). 




Figure 26- Western Blot of Patient 4, urine sample 5, undiluted and also diluted in PBS; 2, 10, 20 and 100 times. 
Each prepared sample, and SpA standards (0.1µg/ml concentration, total volume 7ng), was loaded and 
electrophoresed in SDS-PAGE gel and transferred as per protocol. Membranes were blocked in 2% (w/v) BSA 
and incubated in 1:2000 anti-SpA antibody (constituted in 2% (w/v) BSA). 
 
 
Figure 27- Western Blot of Patient 30, urine sample 5, undiluted and diluted in PBS; 2, 10, 20 and 100 times. 
Each prepared sample, and SpA standards (0.1µg/ml concentration, total volume 7ng), was loaded and 
electrophoresed in SDS-PAGE gel and transferred as per protocol. Membranes were blocked in 2% (w/v) BSA 
and incubated in 1:2000 anti-SpA antibody (constituted in 2% (w/v) BSA). 
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Figure 28- Western Blot of Patient 33, urine sample 5, undiluted and diluted in PBS 2, 10, 20 and 100 times. 
Each prepared sample, and SpA standards (0.1µg/ml concentration, total volume 7ng), was loaded and 
electrophoresed in SDS-PAGE gel and transferred as per protocol. Membranes were blocked in 2% (w/v) BSA 
and incubated in 1:2000 anti-SpA antibody (constituted in 2% (w/v) BSA). 
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The results demonstrate the losses of patient band detection as the samples are diluted, 
losing the majority of band detection at 10 times dilution. More importantly to the 
detection, no bands of equal size to the SpA controls remain and/or appear once samples 
are diluted, meaning that these additional bands are also not diminishing the effect of SpA 
bands in the undiluted samples, at least in patients 4, 30 and 33. As there is no increasing 
signal seen for any particular band following dilution, it was decided to continue using 
patient samples undiluted when testing for SpA. 
Further challenges exist in the analysis of patient samples, as many contained insoluble 
material, which may be sequestering proteins in patient sample WBs. Some of this solid 
matter was in fine grain form, while others were found to exist in the urine as large particles 
larger than 1mm in size. Before continuing to screen patient samples, we performed an 
experiment to finalise the optimal method of preparing samples; either mixing and 
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therefore reconstituting the solid material into the sample, or avoiding it when possible for 
creating a sample for WB. Patients 30 and 33 had a significant amount of solid material in 
some samples, in particular samples 3 (patient 30) and sample 5 (patient 33). These samples 
were each separated into two; one sample contained the pure liquid, which was retrieved 
by spinning down the solid matter into the bottom of the microfuge tubes in a bench-top 
centrifuge. The remaining solid parts of the samples were subject to heating and 
reconstitution, by vortexing, in 100 µl of sterile PBS. Both liquid and solid samples were 
diluted 2, 10, 20 and 100 times with PBS. These samples were both subject to WB on two 
separate membranes, incubating in 1:2000 anti-SpA antibody, in 2% (w/v) BSA (Figure 29 
and 30): 
 
Figure 29- Western Blot of Patients 30 (A) and 33 (B) liquid portion of urine reconstituted in PBS. Each patient 
urine sample was diluted 2, 10, 20 and 100 times in PBS. Each prepared sample, and SpA standards (0.1µg/ml 
concentration, total volume 7ng), was loaded and electrophoresed in SDS-PAGE gel and transferred as per 
protocol. Membranes were blocked in 2% (w/v) BSA and incubated in 1:2000 anti-SpA antibody (constituted in 
2% (w/v) BSA). 
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Figure 30- Western Blot of Patients 30 (A) and 33 (B) solid portion of urine reconstituted in PBS, by heating and 
vortexing. Each patient urine sample was diluted 2, 10, 20 and 100 times in PBS. Each prepared sample, and 
SpA standards (0.1µg/ml concentration, total volume 7ng), was loaded and electrophoresed in SDS-PAGE gel 
and transferred as per protocol. Membranes were blocked in 2% (w/v) BSA and incubated in 1:2000 anti-SpA 
antibody (constituted in 2% (w/v) BSA). 
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In these sample blots, it is evident that the separated liquid produced far fewer bands than 
the reconstituted solid, and no bands at the level concurrent with commercial SpA. Due to 
this paucity of bands seen in the liquid, without prior mixing of solid material, further 
screening of samples would involve vortexing of patient urine in order to retain as much 
solid material as possible. This was seen as giving the highest chance of detecting SpA in 
patient samples, as it may be present as a precipitate or bound to other proteins in the solid 
material.  
Initial observations in the WB method development stage showed 2% (w/v) BSA was a 
superior agent for use in blocking and as antibody solution, as it was more effective in 
removing background signal from purified SpA blots (see Figure 10 and 12). However, these 
experiments only evaluated the WB detection of commercial SpA at different 
concentrations. Given the large number of strong bands of different molecular weight being 
detected in patient urine samples, attempts were made to further define the best agent for 
blocking, when testing patient samples in particular. Retaining the WB sample preparation 
as described, two WB membranes containing SpA controls (PBS and control urine) and a 
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selection of patient urine samples, were both blocked with 5% (w/v) milk. Following this, 
one membrane was incubated in 1:2000 antibody in 2% (w/v) BSA, and the other with 
1:2000 antibody 5% (w/v) milk. The differences in the resulting blots were therefore as a 
result of the antibody binding solution only (Figure 31 and 32). 
 
Figure 31- Western Blot of SpA controls and select patient urine samples, incubated antibody in BSA, with 
associated Amido Black stain. SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient urines 
were electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were 
blocked in 5% (w/v) milk and incubated in 1:2000 anti-SpA antibody, except in 2% (w/v) BSA. This figure 
includes developed Western Blot (A), and Amido black staining of the membrane (B). 
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Figure 32- Western Blot of SpA controls and select patient urine samples, incubated antibody in milk, with 
associated Amido Black stain. SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient urines 
were electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were 
blocked in 5% (w/v) milk and incubated in 1:2000 anti-SpA antibody, in 5% (w/v) milk. This figure includes 
developed Western Blot (A), and Amido black staining of the membrane (B). 
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These WB results clearly demonstrate a significantly increased blocking effect when anti-
SpA antibody was incubated in milk as opposed to BSA. This effect is seen entirely in the 
multiple patient bands that had been previously detected using BSA as antibody solution. 
Not only does diluting antibody in milk prevent the detection of all protein bands in patient 
samples, the ladder bands (which are a mixture of proteins), which were previously 
detected are absent. The 0.1µg/ml SpA standards also appeared to display increased signal. 
These findings together provide strong evidence that the bands previously seen on patient 
sample WB are in fact non-specific urinary proteins, displaying similar binding with anti-SpA 
antibody as the ladder proteins. These non-specific bands appear to correspond to the 
protein bands seen when the membrane is stained with Amido Black. Given the ability of 
the WB method for reliably detecting 0.1µg/ml SpA, and the retention of these SpA 
standard bands when using 5% (w/v) milk as antibody solution, it is reasonable to suggest 
that there is no SpA at, or above, this concentration in the patient samples tested.  
This method of using 5% (w/v) milk as both blocking agent and antibody solution, was 
adopted as the optimised method for the detection of SpA. This retained the sensitivity of 
detecting 0.1µg/ml (or 7ng total volume), SpA, with the beneficial removal of the additional 
bands seen in original patient sample blots. A further experiment was devised in order to 
test the limit of this enhanced blocking effect of milk antibody solution. This was achieved 
by testing SpA standards and patient samples by WB, and increasing antibody concentration 
in 5% (w/v) milk, from 1:1000 to 1:500. This would prove whether the non-specific bands in 
patient urine would once again become visible at higher antibody concentrations, indicating 
that the blocking effect is dose-dependent (Figure 33 and 34). 




Figure 33- Western Blot of SpA standards and patient urine samples, incubated in 1:1000 concentration anti-
SpA antibody. SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient urines were 
electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were blocked in 
5% (w/v) milk and incubated in 1:500 anti-SpA antibody (also in 5% (w/v) milk). Ladder proteins not stained. 
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 Figure 34- Western Blot of SpA standards and patient urine samples, incubated in 1:500 concentration anti-
SpA antibody. SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient urines were 
electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were blocked in 
5% (w/v) milk and incubated in 1:500 anti-SpA antibody (also in 5% (w/v) milk).  Ladder proteins not stained. 
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These blots demonstrate that the blocking of additional bands is not negated by increasing 
the concentration of antibody incubated in 5% (w/v) milk. However, at higher antibody 
concentrations, white bands, or ‘bleached’ bands appear at positions analogous with the 
additional bands seen when the antibody is in a BSA solution. Because of this bleaching 
effect, further testing of patient samples would utilize anti-SpA at a 1:2000 concentration.  
3.1.3 Patient sample testing by Western Blot 
A full sample screening of single patient samples was undertaken, using the optimised WB 
technique and 1:2000 antibody in 5% (w/v) milk. As in previous optimisation experiments, 
samples from the middle of the range were used per patient, with a total of 8 patient 
samples per gel. Similarly to previous blots using milk as antibody solution, these patient 
sample WBs did not produce any positive results for SpA, nor were any additional bands 
present as seen in previous blots of patient samples. These were confirmed as viable 
experiments due to the continued detection of 0.1µg/ml SpA standards, in both control 
urine and PBS (Figure 35). 
 
Figure 35- WB- Western Blot of SpA standards and patient number 37 – 41 urine samples, with associated 
Amido Black stain. SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient urines were 
electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were blocked in 
5% (w/v) milk and incubated in 1:2000 anti-SpA antibody (also in 5% (w/v) milk). This figure includes developed 
Western Blot (A), and Amido black staining of the membrane (B). 
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In order to fully assess the validity of these negative findings, it was important to rule out 
variability of sample composition within the same patient range; i.e. the chances that 
individual samples in a patient sample range were positive, while others were negative. TO 
achieve this, it was decided to test the full sample ranges of particular patients which would 
provide the highest chance of detecting SpA. Patients 4 and 12 were found to contain many 
additional protein bands on Amido Black staining, so were candidates for full sample testing. 
Urine samples from patients 18, 19 and 24 were also fully tested by WB, due to a high 
probability of exposure to S. aureus (Table 2). 
 
Patient  Rationale for full sample range testing 
18 Gram positive bacteria in blood culture 
19 Necrotising fasciitis 
24 Necrotising fasciitis, Gram positive bacterial growth from wound swab 
Table 2- Patient number and diagnosis indicating likely presence of S. aureus. 
 
These full sample range blots, tested using the same method as the previous screening 
experiments, also did not yield any positive results, again appearing blank apart from the 
SpA standards. These negative WB are contrasted with the Amido Black stain displaying 








 Figure 36- Western Blot of SpA standards and patient 18 full sample range, with associated Amido Black stain. 
SpA standards (concentration 0.1µg/ml, total volume 7ng), and patient 18 urine sample range were 
electrophoresed in SDS-PAGE gels and transferred to membrane as per protocol. Membranes were blocked in 
5% (w/v) milk and incubated in 1:2000 anti-SpA antibody (also in 5% (w/v) milk). This figure includes developed 
Western Blot (A), and Amido black staining of the membrane (B. Ladder proteins are non-distinct on the stain. 
 
 Due to these negative WB results, the decision was made to not continue screening patient 
samples by WB. Despite optimising the method and removing almost all non-specific 
binding, the detection limit of our SpA WB, in patient sample testing conditions (7ng SpA) 
was considered insufficient to entirely rule out the presence of SpA in patient samples. This 
prompted the development of a sensitive ELISA technique, in order to continue our search 
for endogenous SpA. 
3.1.4 Western Blot Results Summary 
This work represents the development of a highly specific WB method for the detection of 
commercial, cell-culture purified SpA in sterile PBS and control urine solutions. However, 
application of this technique to testing patient urine has found it to be incapable of 
detecting any endogenous SpA above a solution concentration of 0.1-0.01µg/ml. 
Optimisation of this technique has revealed that multiple strong bands, initially detected in 
patient samples at a variety of MWs using WB, are likely to correspond to non-specific 
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urinary proteins. This is due to their elimination from WB following the switch from BSA to 
milk as a blocking agent and antibody solution, a method which continued to detect SpA 
standards.  
3.2 ELISA Results  
3.2.1 ELISA development for detection of SpA in patient urine 
The development of an ELISA technique for the detection of SpA was based on the method 
developed by Harrison et al and Frances Price (MSc 2013), using an indirect ‘sandwich’ ELISA 
technique. These ELISA techniques have shown high sensitivity for Staphylococcal toxins, as 
previous work by this laboratory had achieved detection of TSST, SEB, SEC and AH, to a 
concentration of 1-3ng/ml.80 
The method chosen for the detection of SpA was an indirect ELISA, using a capture antibody 
to bind to SpA, before using an HRP-conjugated anti-SpA antibody to bind to the IgG-bound 
SpA. Human IgG was used as capture antibody, due to its previously discussed affinity for 
SpA. Several parameters were to be assessed in order to identify the optimal method: 
1. Capture antibody concentration- each microwell was coated in 100µl of 0.5µg/ml or 
1µg/ml commercial human IgG 
2. Blocking solution- following capture antibody, blocking buffer, similar to those used 
in WB, are placed in wells to reduce the non-specific binding ability of the capture 
antibody. Blocking buffers compared in our ELISA were 5% (w/v) milk, and 2.5% (v/v) 
cold water fish gelatine. 
3. Anti-SpA antibody concentration- lower amounts of antibody are usually required for 
ELISAs rather than WB; initial tests compared 1:4000 and 1:8000 anti-SpA 
concentration 
Initial ELISA method development focused on first; establishing the efficacy of the method 
as described for the detection of SpA, and second; to determine the sensitivity limits of the 
methods for SpA detection in PBS solution and urine. To determine if the technique was 
viable for the detection of small amounts of SpA , known concentrations of SpA from 
100ng/ml to 25ng/ml were added to both PBS and control urine, and tested by ELISA using a 
variety of capture IgG concentrations and blocking buffers (Figure 37-40). 




Figure 37- SpA standards in PBS, tested by SpA ELISA, with varying blocking materials. Microwell plates were 
coated with 0.5µg/ml IgG, and blocked with either 5% (w/v) milk or 2.5% (v/v) fish gelatine. SpA standards 




Figure 38- SpA standards in PBS, tested by SpA ELISA, with varying blocking materials. Microwell plates were 
coated with 1µg/ml IgG, and blocked with either 5% (w/v) milk or 2.5% (v/v) fish gelatine. SpA standards were 
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Figure 39- SpA standards in control urine, tested by SpA ELISA, with varying blocking materials. Microwell 
plates were coated with 0.5µg/ml IgG, and blocked with either 5% (w/v) milk or 2.5% (v/v) fish gelatine. SpA 
standards were then added, and finally incubated with 1:4000 anti-SpA antibody. Error bars are standard 
deviation. 
 
Figure 40- SpA standards in control urine, tested by SpA ELISA, with varying blocking materials. Microwell 
plates were coated with 1µg/ml IgG, and blocked with either 5% (w/v) milk or 2.5% (v/v) fish gelatine. SpA 
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The ability to detect SpA on ELISA was confirmed in both PBS and urine, and background 
was low across the plate; average PBS absorbance was 0.052 (SD 0.005).  
In terms of SpA sample absorbance, there was little appreciable difference between 
blocking in 5% (w/v) milk and 2.5% (v/v) fish gelatine; however, control urine background 
was raised when blocked with fish gelatine (0.124) when compared with milk (0.043). This 
corroborates with the superior blocking effect of milk seen in WB, when incubating with 
polyclonal anti-SpA antibody. It was decided to use milk as a blocking agent for ELISA, due 
to a lower background and to maintain consistency with WB method. 
The concentration of primary antibody was investigated by comparing 1:4000 and 1:8000 
solutions, based on concentrations used in ELISA techniques for the detection of other 
Staphylococcal toxins by Frances Price (MSc 2013).80 The 1:4000 antibody solution 
provided higher absorbance range when testing SpA standards in control urine, as well as 
displaying lower standard deviation error bars at the higher-middle range of SpA 
concentration (Figure 41). 




Figure 41- SpA standards (in control urine), tested by SpA ELISA, with varying primary antibody concentration. 
Microwell plates were coated in 0.5µg/ml IgG, then blocked in 5% (w/v) milk. SpA standards were added and 
incubated in either 1:4000 or 1:8000 anti-SpA antibody. Error bars are standard deviation. 
 
As expected, the absorbance of SpA standards on ELISA was higher when using an primary 
antibody at the higher concentration. This was particularly evident at higher standard 
concentrations (100ng/ml SpA) which produced an absorbance of 2.156 with 1:4000 
antibody concentration, compared to 1.338 with 1:8000 antibody concentration. 
However, SpA negative standards produced the same average absorbance (0.043), 
meaning that 1:4000 antibody concentration displayed a greater useful range of SpA 
detection.  
Based on these optimisation experiments, an SpA concentration curve was created by 
SpA ELISA, utilising 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk and 
detected with 1:4000 anti-SpA antibody. The sensitivity of commercial SpA detection in 
PBS and urine can be demonstrated by a concentration curve of SpA samples, starting at 
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Figure 42- SpA concentration curve, with SpA standards constituted in PBS. Commercial SpA standards were 
tested by ELISA using 0.5µg/ml IgG as capture antibody, then blocked in 5% (w/v) milk and incubated in 1:4000 
anti-SpA antibody. Error bars are standard deviation. SpA concentrations were created in a 2x dilution series. 
 
 
Figure 43- SpA concentration curve, with SpA standards constituted in control urine. Commercial SpA 
standards were tested by ELISA using 0.5µg/ml IgG as capture antibody, then blocked in 5% (w/v) milk and 
incubated in 1:4000 anti-SpA antibody. Error bars are standard deviation. SpA concentrations were created in 
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These results demonstrate the ELISA technique to be effective and sensitive for the 
detection of SpA, in both PBS and control urine. Standard deviation was very low 
throughout this curve, confirming the ELISA method optimised to be reliable and sensitive 
for detecting nanogram amounts of SpA. Both PBS and control urine SpA concentration 
curves roughly equate to each other; upper asymptotes are reached between 25-50ng/ml, 
and lower asymptotes are reached at approximately 0.78ng/ml, creating a linear region 
from 25-0.78ng/ml (EC50= 9.37ng/ml). This produced the following linear standard SpA 
curve in control urine, which would allow quantification of SpA in patient samples (Figure 
44). 
 
Figure 44- SpA ELISA of SpA standards in PBS, creating a standard curve with trend line through linear region. 
SpA standards were tested by ELISA using 0.5µg/ml IgG as capture antibody, then blocked in 5% (w/v) milk and 
incubated in 1:4000 anti-SpA antibody. 
3.2.2 Screening Patient Urine Samples for SpA 
Following the development of a method for the detection of 1ng/ml of SpA in control urine, 
we performed a screening experiment by testing a single sample from each available patient 
range (patient n=45). This was done as an initial pilot experiment due to the potential for 
interaction between the large amounts of protein in patient urine, and the anti-SpA 
antibody. An initial ELISA would be useful to rule out this result, and in order to confirm this 
technique as sensitive and specific. 
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blocked in 5% (w/v) milk, and incubated in 1:4000 anti-SpA antibody. Only 1 well was used 
per patient sample, at 100µl/well, in an attempt to limit overuse of patient samples. 
Results of the initial experiment were promising, with an average background of 0.053. 
Several samples displayed a raised absorbance corresponding to low levels of SpA (1.562 - 
3.125ng/ml), while others showed absorbance no greater than background (PBS) level. 
Given that only 1 well was used per patient sample, the experiment was repeated with 2 
wells per patient sample, using the same patient samples as previously. This experiment 
concurred with the increased absorbance seen in certain patient samples, compared to 
control urine and PBS background, leading to the decision to test more patient samples. 
 Full sample-range testing was conducted for 241 (79%) of patient urine samples. Patient 
samples were not tested if there was insufficient volume of sample, or there were 
unavailable samples in that range. The figures below display the absorbance on ELISA for the 
patient ranges containing 1 or more samples positive for SpA. Patients with entirely 
negative sample ranges are not displayed (Figure 45A – 45L, 46A - 46D and 47). 
 




Figure 45A- 45L - Patient urine sample ranges, tested by ELISA, with mildly raised absorbance (0.0- 0.5 at 450nm). SpA 
ELISA was performed with 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk and incubated in 1:4000 anti-SpA 
antibody. Patient samples were tested at a volume of 100µl, undiluted. 











Figure 46A- 46D- Patient urine sample ranges, tested by SpA ELISA, with moderate raised absorbance (0.0- 1.0 at 
450nm). SpA ELISA was performed with 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk and incubated 
in 1:4000 anti-SpA antibody. Patient samples were tested at a volume of 100µl, undiluted. 
Figure 47- Patient 13 sample range absorbances tested by SpA ELISA. Patient 13 is the only sample with absorbance 
between 0.0 - 3.0 at 450nm. SpA ELISA was performed with 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk 
and incubated in 1:4000 anti-SpA antibody. Patient samples were tested at a volume of 100µl, undiluted. 
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Of the 241 patient samples tested for SpA, 55 samples (22.81% of those tested), derived 
from a total of 16 patients, showed a significantly raised absorbance, indicating the 
presence of SpA. The majority of these patients (e.g. Figure 48A- 48L) displayed an 
absorbance corresponding to very low concentrations of SpA (<1ng/ml). Only 5 patient 
ranges contained samples which displayed an absorbance above this level (1-5ng/ml), while 
one patient (patient 13) displayed an absorbance significantly above this level (5-15ng/ml). 
Of the patients with full sample ranges tested for SpA by ELISA, 16 patients did not contain a 
single sample with a significantly raised absorbance. 
These patient sample range graphs also provide temporal information about the variation of 
SpA ELISA result over the course of the 48 hour ICU admission. In this patient group, there 
did not appear to be any relationship over time, with adjacent urine samples (taken 6 hours 
apart) displaying high variability. 
3.2.3 Comparison of ELISA with Western Blot results 
Following full sample range ELISAs, the patient samples with highest SpA ELISA absorbance 
were selected for re-testing by WB, in order to discover if bands of SpA could be visualised. 
Patients tested by both ELISA and WB were 13 and 36, as these were found to contain the 
highest potential concentration of SpA. Each patient sample range was treated as per WB 























P013-01 0.055 0.11 
 
P013-02 2.802 15.765 
 
P013-03 1.584 8.826 
 
P013-05 2.409 13.526 
 
P013-06 0.429 2.239 
 
P013-07 0.453 2.377 
 
Table 3- Patient 13 full sample range absorbance on SpA ELISA, and estimated concentration of SpA based on 
SpA standard concentration. 
 
 
Figure 48- Western Blot of Patient 13 samples 1-7, with SpA standards and Precision Plus protein standards 
(ladder). Patient urine samples and standards were electrophoresed and transferred to membrane as per 
Western Blot protocol, blocked in 5% (w/v) milk and incubated with 1:2000 anti-SpA antibody. This figure 
displays the developed blot (A) and Amido Black stain of the same membrane (B). 
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P036-01 0.156 0.685 
 
P036-02 0.475 2.502 
 
P036-03 0.276 1.369 
 
P036-04 0.475 2.503 
 
P036-05 0.916 5.018 
 
P036-06 0.042 0.035 
 
Table 4- Patient 36 full sample range absorbance on SpA ELISA, and estimated concentration of SpA based on 
SpA standard concentration.  
 
Figure 49- Western Blot of Patient 36 samples 1-6, with SpA standards and Precision Plus protein standards 
(ladder). Patient urine samples and standards were electrophoresed and transferred to membrane as per 
Western Blot protocol, blocked in 5% (w/v) milk and incubated with 1:2000 anti-SpA antibody. This figure 
displays the developed blot (A) and Amido Black stain of the same membrane (B). 
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These results demonstrate definitively that the high absorbance results seen when testing 
patient urine by ELISAs, a raised absorbance does not translate to positive findings on WB 
using the same antibody. Amido Black stains of the membranes following WB display the 
presence of protein bands, and the identification of 0.1µg/ml SpA standards show that any 
SpA at that concentration should have been identified. However, in terms of total SpA 
identified, WB can detect ~7ng, while ELISA is more sensitive, capable of detecting SpA 
standards of <1ng/ml. Only patient 13 contains samples with ELISA results which may 
indicate levels of SpA that may cross the WB detection limit (~15ng/ml), however, these 
samples do not display bands on WB.  
These results suggests that either our WB developed for SpA does not have the sensitivity to 
detect biologically relevant levels of SpA, or SpA is not present in the urine samples, and the 
raised absorbance seen on ELISA is the result of non-specific binding with urinary proteins. 
Further experiments which could provide evidence of non-specific binding were undertaken 
before the results of our ELISA could be definitively stated as endogenous SpA. 
3.2.4 ELISA for detection of total IgG in patient urine 
We were aware of the potential for the cross-reaction of the antibody with urinary proteins 
and IgG, as seen on initial patient sample WBs. Therefore, we decided to quantify total IgG 
and protein in a certain ELISA positive and negative patient urine samples, to statistically 
determine if these contributed to the raised absorbance seen in positive SpA ELISA results. 
3.2.4.1 ELISA technique development for detection of total IgG 
An IgG ELISA was theorised to be achievable through two methods; direct adsorbance of IgG 
to the microwell plates, followed by incubation in anti-human IgG antibody (HRP-
conjugated), or initial adsorbance of SpA to the microwell plates for use as a capture 
antigen, followed by incubation in sample, and finally incubation in anti-Human IgG 
antibody. IgG curves were created from an initial concentration of 500µg/ml, with the 
concentration reduced by half in 18 steps in order to reach the lowest concentration of 
3.8ng/ml.  
For the experiments investigating SpA as capture antigen, either 1µg/ml or 0.5µg/ml SpA 
was adsorbed onto microwell plates, overnight at 40C. Following the formation of IgG curve 
samples in carbonate-bicarbonate buffer, and incubation in anti-Human IgG antibody, an 
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IgG curves was produced for each adsorption technique. All IgG concentrations had 
background absorbance subtracted before inclusion into the curve (Figure 50). 
 
Figure 50- IgG ELISA concentration curves, tested on a microwell plate coated with either 0.5µg/ml or 1µg/ml 
SpA. Standards were incubated on microwell plates overnight at 40C. Following incubation, plates with blocked 
in 5% (w/v) milk and incubated in 1:4000 concentration anti-human IgG antibody. Error bars are standard 
deviation. IgG standards were created from a 500µg/ml solution in a 2x dilution series, and are  
 
PBS background absorbance was significantly raised on the plate containing 1µg/ml, hence 
the lower absorbance of the curve after subtraction of the background. For the IgG curve 
created with 0.5µg/ml SpA as capture antigen, background was 0.712, and for 1µg/ml SpA 
background was 1.417.Low ELISA absorbances seen in these curves were the result of 
subtracting these high background from standard absorption. As well as this high 
background, standard deviation error bars through the linear region were large. Both of 
these limiting factors meant that the method of using SpA as capture antigen was deemed 
unacceptable for detection of endogenous IgG in patient urine.  
An alternative method of IgG detection, would be to IgG adherence to microwell plates 
without capture antibody, developing a direct ELISA. To achieve this, IgG concentration 
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adherence to microwell plates. Following adherence, 5% (w/v) milk was used as blocking 
agent, and anti-IgG antibody was then applied (Figure 51). 
 
Figure 51- IgG ELISA concentration curve, tested by IgG ELISA, on a microwell plate coated directly with sample 
overnight at 40C. Following standards adsorption to plates, they were blocked with 5% (w/v) milk and 
incubated in 1:4000 anti-human IgG antibody. Error bars are standard deviation. 
 
Background was low, with an average of 0.047 for PBS, similar to levels seen in ELISA 
experiments testing for SpA using IgG as capture antibody, while remaining sensitive for IgG 
down to 7ng/ml. It was decided to use the overnight direct adsorbance method for 
detecting IgG in patient samples. However, the standard curve would ideally be in the same 
solution as the samples being tested, which would be urine.  
If patient samples would to be constituted in carbonate-bicarbonate buffer, as in the curve, 
a 1:1 solution with 2 times carbonate-bicarbonate buffer would be used. This would mean 
that the true concentration of IgG in patient samples would be double that measured by 
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Figure 52- IgG Standard Curve, of human IgG standards constituted, in carbonate-bicarbonate buffer. Linear 
region of curve is displayed. IgG standards were tested by direct IgG ELISA, blocked with 5% (w/v) milk and 
incubated with 1:4000 anti-human IgG antibody. 
 
3.2.5 ELISA for total IgG in patient urine 
Using the method developed for detecting total IgG on ELISA, samples which were positive 
on SpA ELISA were retested for IgG, alongside a control group of negative SpA ELISA 
samples. This could be a possible cause of false-positive results in SpA ELISA; if large 
numbers of urinary IgG molecules remain bound to capture IgG, it could non-specifically 
bind to anti-SpA antibody. Total number of patient samples tested for IgG was 33, 15 SpA 
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1(2) 0.063 1.787 428.4 
2(5)  0.091 1.687 401.8 
5(6)  0.122 1.515 239 
9(1)  0.700 0.363 48.6 
 
10(2)  0.063 1.893 456.6 
12(5)  0.117 1.987 481.8 
13(2)  1.992 0.337 41.6 
25(1)  0.109 1.465 342.6 
31(5)  0.076 2.581 640.2 
34(3)  0.229 0.528 92.6 
36(5)  1.044 0.445 70.4 
38(2)  0.059 1.047 231.2 
39(2)  0.150 1.995 483.8 
42(6)  0.102 1.568 239 
44(3)  0.060 1.846 444.2 
Table 5- Patient samples displaying highest absorbance for SpA, retested by SpA and IgG ELISA. Estimated 



















4(3) 0.053 2.106 513.5 
6(5) 0.056 1.804 433.1 
11(5) 0.051 0.464 75.6 
18(5) 0.047 2.136 521.6 
19(3) 0.049 1.761 421.6 
21(1) 0.091 0.525 91.8 
22(1) 0.061 2.380 586.7 
24(3) 0.066 1.847 444.6 
28(6) 0.056 1.109 247.7 
29(3) 0.072 1.719 410.3 
30(3) 0.046 1.042 229.9 
32(1) 0.047 1.704 406.3 
33(2)  0.059 1.462 341.7 
35(1)  0.053 1.490 349.2 
37(1)  0.054 1.508 353.9 
40(4)  0.053 1.496 350.9 
43(7)  0.050 0.563 101.9 
47(3)  0.051 1.359 314.4 
Table 6- Patient samples displaying lowest absorbance for SpA, retested by SpA and IgG ELISA. Estimated 
concentration of IgG in patient urine samples is calculated by IgG ELISA. 
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Statistical analysis on the levels of IgG absorbance revealed no difference between these 2 
groups. Mean absorbance for IgG in positive samples was 1.471 (95% CI 1.196-1.746), and 
for negative samples was 1.403 (95% CI 1.017-1.789), giving a non-significant p-value of 
0.7570. Given the significant difference between the two groups for absorbance when 
tested for SpA, this was seen as evidence that the presence or absence of IgG in the patient 
samples did not affect the absorbances seen when testing for SpA by ELISA. 
These IgG ELISAs proved that IgG is present in variable amounts in patient urine samples, 
and the presence of IgG was not significantly raised in the patient samples with highest SpA 
ELISA absorbance. 
3.3 Bradford Assay of Patient Samples 
Following indication that the amount of total IgG is not producing false positive absorbances 
in patient samples, the same sample range was tested for total protein content. This was to 
rule out non-specific interaction with urinary proteins (such as albumin) as the sole cause of 
positive SpA ELISA results. It was previously shown that the polyclonal anti-SpA antibody 
used in WB had the potential for non-specific binding, especially when in BSA solution. 
However, whether this phenomenon also occurred with non-denatured samples, tested by 
ELISA, was unknown. 
To estimate total protein in patient samples, a standard protein curve was made, as detailed 
in the methods. Following measurement of absorbance, a standard protein curve was 
created (Figure 53). 




Figure 53- BSA standard curve, equalised against a blank of NaCl. BSA standards were tested by Bradford assay 
as per protocol. BSA standards were created from a 1.5mg/ml BSA solution, in a 2x dilution series.  
 
Each patient sample, previously tested for SpA and IgG by ELISA, was retested for total 
protein, using the method as described for creating protein standards. The results are 
































BSA Concentration (µg/ml) Log Scale 
BSA Protein Assay Curve 












1(2) 0.112 0.292 




9(1)  1.35 3.523 
10(2)  0.722 1.884 
12(5)  0.284 0.741 
13(2)  0.703 1.834 
25(1)  0.549 1.432 
31(5)  0.254 0.662 
34(3)  0.045 0.116 
36(5)  0.543 1.417 
38(2)  0.192 0.501 
39(2)  0.803 2.095 
42(6)  0.81 2.114 
44(3)  0.802 2.093 
Table 7- Patient samples most positive for SpA by ELISA, tested for total protein content by Bradford Assay 
















4(3) 1.66 4.333 
6(5) 0.354 0.924 
11(5) 0.311 0.812 
18(5) 0.266 0.694 
19(3) 0.513 1.339 
21(1) 0.253 0.660 
22(1) 0.245 0.639 
24(3) 0.494 1.289 
28(6) 0.422 1.101 
30(3) 0.28 0.730 
32(1) 0.572 1.492 
33(2)  0.507 1.323 
35(1)  0.794 2.072 
37(1)  0.299 0.781 
40(4)  0.933 2.435 
43(7)  0.76 1.983 
47(3)  0.376 0.981 
Table 8- Patient samples negative for SpA by ELISA, tested for total protein content by Bradford Assay 
absorbance, with estimated protein concentration 
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 Statistical analysis performed on the Bradford Assay absorbances showed no significant 
difference between positive and negative patient groups. Mean protein assay absorbance 
for the positive group was 0.583 (95% CI 0.388-0.779), and for the negative group was 0.532 
(95% CI 0.348-0.715), giving a non-significant p-value of 0.6808 for the difference in the 
means, as tested by Student’s T-Test. This provided evidence that the total amount of 
protein in patient samples was not the sole contributing factor to a raised absorbance seen 
on SpA ELISAs. However, given the small sample population tested for both total IgG and 
protein, only limited conclusions can be drawn from this information. 
3.4 Boiling patient urine and serum samples 
As the patient samples and control urine are known to contain IgG, it was hypothesised that 
this may be found bound to endogenous SpA, reducing its ability to bind to the capture IgG 
during the initial phase of an SpA ELISA. This sample attenuation by IgG would also apply to 
SpA concentration curves, as they have been constituted in control urine in the course of 
this research. The ELISA method for SpA detection in human serum, developed by Nilsson et 
al, showed clear evidence of SpA-IgG binding in human serum, which could be broken by 
boiling the serum for 10 minutes.183 In this study, it was found that without boiling, the 
absorbance of SpA standards constituted in human serum was not raised above background 
level, while following boiling, the SpA concentration curve in serum equated to levels seen 
in PBS solution.183   
Using this information, we repeated this experiment by creating an SpA concentration curve 
in control urine, and we subjected one curve’s samples to heating at 980C for 10 minutes. 
Both sets of SpA standards in control urine were treated as per SpA ELISA method, with the 
only independent variable being the heating of samples (Figure 54). 




Figure 54- SpA concentration curves, constituted in control urine, tested non-boiled and following boiling for 
10 minutes. Commercial SpA was added to undiluted control urine to create a concentration curve. SpA ELISA 
was performed with 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk and incubated in 1:4000 anti-
SpA antibody. SpA standards were constituted in a 2x dilution series, in control urine. 
 
These curves show that the sensitivity for SpA in ELISA is increased when control urine 
standards are boiled prior to testing, with the concentration curve displaying a shift to the 
right. This correlates with the findings of Nilsson et al, and demonstrates that a certain 
amount of SpA in patient urine samples may be quenched by the binding action of human 
IgG.183 Furthermore, it shows that the SpA molecule is capable of tolerating boiling for 10 
minutes, with anti-SpA binding retained.  
3.4.1 Protein A Standards in serum 
In order to confirm the potential quenching effect of IgG in commercially sourced healthy 
human serum on detecting SpA by ELISA, a series of SpA standards was made up in a sample 
of commercial human serum. These standards were prepared at 400ng/ml, 40ng/ml and 























SpA Concetration (µg/ml) Log Scale 
SpA Standard Curve in Control urine- 
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3 samples were tested non-boiled, and the same samples were also tested after 10 minutes 
of heating at 980C. Each serum sample was diluted 1:5 with dH20, in order to avoid 
solidification of the serum sample on heating (Figure 55). 
 
Figure 55- Comparison of commercial SpA detected by SpA ELISA, when added to human control serum. 
Standards were tested non-boiled and following boiling for 10 minutes. SpA standards were constituted in 
human control serum, and diluted 1:5. SpA ELISA was performed with 0.5µg/ml IgG as capture antibody, 
blocked in 5% (w/v) milk and incubated in 1:4000 anti-SpA antibody. 
 
This result clearly demonstrates the quenching effect seen in serum, most likely due to the 
effect of IgG binding to SpA and blocking binding to the capture antibody. On boiling, these 
existing bonds are likely to be broken, freeing up SpA binding sites. To confirm the presence 
of IgG in the commercial serum, a separate ELISA dilution test was performed, which was 
positive; the healthy serum was calculated to contain 9.85mg/ml total IgG. Again, this also 
demonstrates the viability of commercial SpA detection by ELISA after boiling for 10 
minutes. 
3.4.2 Testing patient samples after boiling 
The logical next step in investigating this effect was an ELISA retest of SpA positive and 
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SpA ELISA signal, then patient urine samples which were initially negative may become 
positive, while positive ELISA samples may display increased signal. This experiment was 
conducted with two groups of urine samples, three SpA ELISA positive samples and 3 SpA 
ELISA negative samples. These were tested both untreated, and after heat treatment for 10 
minutes, meaning each urine sample was tested twice (Table 9 and 10). 
 
Positive Samples Non-boiled 
Absorbance 
Boiled absorbance 
9 0.068 0.046 
9 0.102 0.051 
34 0.571 0.042 
34 0.777 0.041 
36 2.763 0.041 
36 2.769 0.067 
Table 9- Positive urine samples tested by SpA ELISA, with samples tested non-boiled and following boiling. 
 
Negative Samples Non-boiled 
Absorbance 
Boiled absorbance 
4 0.047 0.041 
4 0.041 0.040 
18 0.046 0.042 
18 0.051 0.044 
24 0.071 0.043 
24 0.064 0.039 
Table 10- Negative urine samples tested by SpA ELISA, with samples tested non-boiled and following boiling. 
 
These samples demonstrate that after 10 minutes of boiling, these patient samples display 
no higher absorbance than background (PBS background 0.047- SD 0.011). This is the 
opposite to what was expected from this experiment, if we are detecting SpA, as it is heat 
tolerant and should have raised signal following dissociation from IgG. 
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Not only is heating capable of eliminating positive ELISA results, but it was found to be 
capable of this effect after only a short amount of heating time. Within only 3 minutes of 
boiling, 8 patient urine samples, which initially showed a range of absorbance on SpA ELISA, 
became uniformly negative, which indicated that the non-specific binding, or protein, is 
denatured quickly (Figure 56). 
 
Figure 56- Patient urine samples tested by SpA ELISA, before heating, after 3 minutes heating and 5 minutes 
heating (including background). Each patient urine sample was tested once at each temperature. SpA ELISA 
was performed with 0.5µg/ml IgG as capture antibody, blocked in 5% (w/v) milk and incubated in 1:4000 anti-
SpA antibody. 
 
This figure shows the complete reduction in absorbance following a short amount of heating 
at 980C.  
Concurrent with the collection of urine samples, a single sample of serum was collected at 
the start of each patient ICU admission. This preparation of SpA ELISA samples by boiling 
was tested in these patient serum samples, to identify if signal increases in certain samples 
after boiling. A collection of 40 patient serum samples (1 serum sample per patient) was 
independently tested for SpA by ELISA, and the same samples were tested for SpA following 
10 minutes of boiling. Like the control serum used to constitute SpA standards (Figure 58), 
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of the patient samples displayed an absorbance above that of background (PBS background 
0.064- SD 0.005).  These patient samples displayed no increase in absorbance following 
boiling; no samples displayed a significant increase in absorbance from background. 
3.4.3 ELISA Conclusions 
We have developed a sensitive ELISA for SpA, using IgG as capture antibody, which was 
capable of detecting commercial SpA down to physiological levels in PBS and control urine. 
It is also able to be detected in serum by the same method, but only after serum samples 
are boiled. IgG is suspected to cause a quenching effect on commercial SpA detection in 
both urine and serum, an effect which is reversed fully by heating.  
Initial positive ELISA results in patient urine samples, thought to be due to low levels of 
endogenous SpA, become negative on heating, indicating that the protein or molecule 
which caused a raised absorbance in these samples was not heat-resistant. From this, we 
can conclude that the substance responsible for a raised absorbance in these samples is not 
the same molecule as the commercially purified SpA. 
3.5 Mass Spectrometry Results 
In order to identity the substance causing a raised ELISA absorbance in patient urine, an LC-
MS method using samples created by in-gel digestion was devised. The aim was to identify 
the presence of SpA in positive ELISA samples, and to achieve this, 14 patient samples were 
prepared by on two SDS-PAGE gels. Following staining with Coomassie Blue, a band, 
selected on the gel at the same MW as commercial SpA, was excised from each patient 
sample well, and subject to in-gel digestion. Excised bands were sufficiently sized in order to 
encompass a range of MWs from ~47-53kDa (Figure 57).  




Figure 57- SDS-PAGE gel of SpA and BSA standards, and 6 patient samples, electrophoresed for 1.5 hours. Gels 
were then stained with Coomassie Brilliant Blue. Red boxes indicate bands excised to form MS samples. 
 




















For Mascot search results, each search result is given a score, and the significance level is a 
cut-off score above which results have a >5% chance of not being a random event. In this 
chapter, the score will only be presented if it is significantly higher than this level.  
In order to confirm LC-MS as capable of detecting SpA, and what form it is able to detect it, 
a sample of commercial SpA at concentration 500µg/ml was tested, following SDS-PAGE 
electrophoresis and in-gel digestion. Also in order to confirm the efficacy of the machine, 










Top Hits Score Molecular 
Weight (kDa) 
SpA 100µg/ml  IMMUNGLOBULIN G BINDING PROTEIN A 
PRECURSOR (Staphylococcus aureus) 
1153.34 53.7 
Structural Protein A (Staphylococcus aureus) 1065 53.2 
Protein A (Staphylococcus aureus) 1018 35.1 
Protein A (Staphylococcus aureus) 795 38.02 
BSA 1mg/ml Albumin (Bos taurus) 2107.87 71.2 
Table 11- SpA and BSA standards, from SDS-PAGE and in-gel digestion, with LC-MS protein identification, score 
and estimated mass of identified proteins. 
 
The results of the SpA standard experiments confirmed the efficacy of the method of in-gel 
digestion used for processing patient samples, and the ability for the BioTools program to 
confirm the presence of SpA. Interestingly, the commercial SpA from S. aureus strain 8325 
was shown to be constituted of different forms of SpA, of different molecular weights. 
Mainly these constituted SpA at 53kDa and another protein, identified at SpA, at 35kDa and 
38kDa. 
The top hits found by MS for each patient individual patient sample, tested from the middle 
of the sample range (14 samples- see Figure 60 and 61), were found to contain no SpA in 
any form recognised by the BioTools software. The most common detectable protein 
product, with no search filters applied, was alpha-1 glycoprotein and albumin, two proteins 
commonly found in urine. Furthermore, only these proteins were above the significance 
levels for these searches (chance of random detection >5%). When search filters were 
applied to detect only bacterial protein products, a wide variety of different species 
molecules were detectable, but with no hits at scores higher than the significance level. This 
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The decision was made to test certain patients sample ranges, based on the patients which 
displayed positive SpA ELISA results, and diagnostic information. These patients were: 
1. Patients 13 and 36- chosen as they displayed the highest absorbance on SpA ELISA  
2. Patient 18 and 24- both independently positive for Gram-positive bacterial infection, 
from blood culture and wound swab respectively. 
These patients full sample range were run on a single SDS-PAGE gel, and excised as one 
large band, at MW ~47-54kDa. The top results for these samples are displayed below, with 
only the significant hits displayed (Table 12). 
Patient 
sample 
Top Hits- all 
results 












18 Albumin (Bos 
taurus) 






162.3 Fusion Protein: 






475.2 Fusion Protein: 












Table 12- Full sample ranges of patient tested, and band excised at level of commercial SpA. Top hits with 
scores are displayed. 
SID: 33007675                                                                                                                        Christopher Varley 
107 
 
As stated, these patient samples demonstrated clear detection of expected urinary proteins 
(such as alpha-1 acid glycoprotein), but no significant detection of SpA. As these samples 
represented the best chance of detection, based on previous research, this suggests the 
absence of SpA in these patients at the MW of commercial SpA.  
Due to the chance of SpA being present in urine samples at different MW, or small products 
of SpA breakdown being present lower in the gel, it was decided to create samples for LC-
MS which would contain all the products of a urine sample. This was achieved by placing 
patient samples into SDS-PAGE gels, and applying electrophoresis for 10 minutes only, 
thereby eliminating small charged molecules and leaving all large molecules and proteins in 
a single compressed region. This region was excised and halved to create two samples per 














Figure 58- Patient 36 samples on SDS-PAGE to create MS samples for complete urine samples. Patient urine 
samples were electrophoresed for 10 minutes, before staining with Coomassie Brilliant Blue. Red boxes 
indicate excision boundaries, the subsequent gel pieces formed became MS samples 36-1 and 36-2. 
 
Lane 1 2 3 4 5 6 















Figure 59- Patient 13 samples on SDS-PAGE to create MS samples for complete urine samples. Patient urine 
samples were electrophoresed for 10 minutes, before staining with Coomassie Brilliant Blue. Red boxes 
indicate excision boundaries, the subsequent gel pieces formed became MS samples 13-1 and 13-2. 
 
Lane 1 2 3 4 5 6 
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Once these samples were analysed, as expected, many significant hits for urinary protein 
were found, though again, none of these included SpA. This occured even when anlysis was 




Top Hits- all 
results 

























36-1 Sequence 92 





















Table 13- Full range of samples with all bands excised, allowing the complete sample to be tested. Only top 
hits and scores displayed. 
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In summary, these LC-MS sample analyses have shown no evidence of the presence of SpA, 
in a small sample of patient urine samples. However, as these samples have been chosen 
specifically for their relation to S. aureus infection, and their positive ELISA results, we have 
given ourselves the highest chance of detecting the molecule. The lack of positive SpA 
identification may be due to number of factors, which are discussed in the limitations of this 
study. 
3.6 Statistical results and patient characteristics  
In order to obtain further information which might help determine the identity of the non-
specific binding molecules found in ELISA testing, statistical analysis was performed, looking 
at clinical and biochemical variables obtained when urine samples were collected. Basic 
statistics of the 47 patients, such as mortality rates, diagnosis and treatment, were 
performed by Frances et al.80 
Statistical analysis was performed using the Stata (Edition 12) program, with inputted data 
from ELISA experiments and collected clinical data. The aim of this was to reveal which 
characteristics, clinical or biochemical, were significantly associated with a raised 
absorbance seen on SpA ELISA, and whether these results indicated a link to infection. 
In order to perform statistical analysis, ELISA results were dichotomised as ‘positive’ 
(absorbance >0.100) and ‘negative’ (absorbance <0.100). Absorbance was set at the high 
level of 0.100, compared to an average background absorbance of 0.038-0.055, in order to 
ensure all true positives are contained within the positive group. Based on these groupings, 
basic statistics on SpA ELISA results were collected (Table 14). 

















305 241 (79.02%)  
 
60 (24.9%)  
 
181 (75.1%)  
 
Table 14- proportion of positive and negative patient urine samples on SpA ELISA, based on a cut-off value of 
0.100 at 450nm. 
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Statistical analysis was performed comparing these two groups by continuous variables, 
related to clinical status. Based on 6 clinical findings, heart rate, respiratory rate, 
temperature, pH, white cell count and CRP, there was no statistical significant differences in 













Error of the 
Mean 
P Value  
Heart Rate 92.268 93.517 1.251 2.546 0.624  
Respiratory 
Rate 
19.811 21.624 1.812 1.813 0.128  
Temperature 37.436 37.461 0.025 0.11 0.82  
pH 7.382 7.393 0.011 0.015 0.454  
White Cell 
Count 
13.412 12.936 0.477 0.924 0.606  
CRP 211.518 229.86 18.342 20.702 0.377  
Table 15- statistical analysis of clinical variables between positive and negative groups on SpA ELISA. 
 
This indicates that the substance which is causing a raised absorbance in SpA ELISA is not 
related to traditional markers of infection. When patient diagnosis was categorised as 
infectious or non-infectious, comparison between ELISA result groups showed that there 
were more non-infective diagnoses within the ‘positive’ group. This is the opposite result to 
what could reasonably be assumed, if SpA was the cause of the raised ELISA absorbance, 
providing further evidence that the results are due to non-specific binding. 
Further statistical analysis revealed a strong, significant, association between a raised SpA 

























13.665 9.098 4.566 0.969 0.001 (yes) 
Serum 
Creatinine 
169.55 86.209 83.34 12.906 0.001 (yes) 
Table 16- variables associated with renal failure, compared between SpA ELISA positive and negative samples, 
tested by Student’s T-test. 
 
Patients with eGFR > 60 (normal renal function), and <60 (renal failure) were split into two 
groups, and the groups were subject to logistic regression to predict the odds of renal 
failure being present in samples with a positive SpA ELISA result. Incidence of renal failure 
was found to be significantly increased in SpA ELISA positive patients (odds ratio: 4.28, p-
value 0.001). 
 
In summary, patients with evidence of renal failure were likely to produce urine which 
caused a raised absorbance on SpA ELISA. However, whether those patients exhibited 
kidney damage (and therefore glomerular leakage), which would allow large molecules into 
the urine, is not known. It is also a possibility, given the association with a reduced eGFR, 
that these patients produced more concentrated urine, implying an increased concentration 










The primary aim of this research was to develop methods to detect commercially sourced 
SpA via WB and ELISA, and apply those techniques to the detection of endogenous SpA in 
ICU patient urine samples. Mass spectrometry methods were developed to provide an 
additional insight into patient samples, in order to confirm the results of WB and ELISA. This 
information would then be used to assess the viability of SpA as a biomarker for S. aureus 
infection or bacteraemia in the ICU setting. The research to be conducted would involve 
three main stages: 
1. The development of a sensitive WB technique for detection of commercial SpA, and 
the application of the technique to testing ICU patient samples. 
2. The development of a sensitive ELISA technique for detection of commercial SpA, 
and the screening of patient samples by ELISA for endogenous SpA. 
3. Preparation and testing of patient samples by LC-MS. 
4.1 Detection of Protein A by Western Blot 
Previous work conducted by Yue Han proved that detection of commercial SpA by a WB 
method is possible,187 and many other studies investigating the structure of SpA have also 
utilised this approach to confirm the presence of SpA, for example in cell culture.114, 117 The 
work reported here has confirmed this technique as efficacious and specific for commercial 
SpA detection, using a primary (HRP conjugated) polyclonal anti-SpA antibody. The 
detection of SpA was possible down to the nanogram range, shown to be physiological 
relevant, based levels of other Staphylococcal urinary toxins (TSST-1, SEB) quantified by 
Harrison et al.79 Solutions containing 0.1µg/ml SpA produce a reliable and strong signal on 
WB, while there is variable and weak detection of solutions of 0.01µg/ml SpA. These 
concentrations represent a total of 7ng – 0.7ng of SpA per sample.  The higher of these two 
figures was set as the lower limit of detection when applying the method to patient 
samples, as it could be certain that 0.1µg/ml SpA could be detected even in less than 
optimal sample conditions. 
During the course of method development, we observed a number of issues which required 
resolving prior to using the method to test patient samples; these included variations in 
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commercial SpA band size seen on WB, differences in signal strength of SpA when diluted in 
buffer or urine, and the effect of antibody incubation in milk or BSA. 
4.1.1 Differences in Protein A size and bands 
The commercially sourced SpA used in WB standards was purified from cell culture of SpA-
producing S. aureus strain 8325, using an IgG-affinity column. This was documented in the 
product information as MW 42kDa; however, as seen in our SpA WB (e.g. Figures 16 and 
17), the product was detected as two distinct bands at the larger size of ~50-55kDa. We 
initially thought this could be due to phenomenon known as ‘gel shifting’, a phenomenon 
primarily seen when cell membrane proteins are subject to electrophoresis in SDS-PAGE 
gels, and can result in bands at MWs higher than expected.189 However, other reports, in the 
literature, including genetic studies on SpA secretion by strain 8325, established the MW of 
SpA as ~58kDa.115 This was confirmation that our WB results were displaying the correct 
MW for the particular S. aureus strain, though ‘gel-shifting’ may explain slight variation in 
MW seen between blots. 
Commercially sourced SpA was consistently identified as a double band upon examination 
by WB, with the higher MW band displaying marginally increased signal, implying a higher 
concentration (e.g. Figure 20).  These multiple bands were initially believed to be 
contamination from a separate protein; IgG was a likely candidate, as this was used to purify 
the SpA from culture, and the heavy chain of IgG is of approximate MW of 50kDa.188 
However, LC-MS investigation of multiple SpA bands, separated by electrophoresis, showed 
that each band contains SpA, but of different MWs (38-55kDa). This experiment also 
excluded the contamination of IgG (or other proteins) in the commercially sourced SpA. 
One explanation for multiple bands of the same protein is protease degradation during 
storage of SpA, which can cause of proteins to run at a different MW or appear as a double 
band.190 However, another possibility, backed by evidence in the literature, is that the 
commercial SpA culture medium contains different variants of SpA.. One study identified an 
enzyme (LytM) which actively cleaves SpA from the cell wall, producing a secreted form of 
SpA which included peptidoglycan amino acid residues; these residues contribute 
approximately 3-5kDa to the whole SpA molecule.137 Another study by O’Halloran et al, into 
the structure of secreted forms of SpA, discovered that the protein can be found secreted 
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without evidence of prior incorporation into the cell wall, with precursor molecule regions 
(e.g. C-terminal sorting signal) unprocessed.139 That study found that this purely secretory 
form of SpA measured at 51.9kDa, while variants of SpA, displaying prior inclusion to the cell 
wall, measured between 52kDa and 54kDa. This is evidence that SpA can be found in a 
number of forms in culture, at different MWs. The commercial purified SpA used in our WB 
experiments is from a single culture source, we suggest that we are seeing a mixture of cell-
wall associated SpA and a secreted variant, also explaining the identification of both bands 
as SpA by LC-MS.  
4.1.2 Effect of sample solution on detection of Protein A 
In the WB method optimisation stage, signal attenuation of commercial SpA was noted 
when SpA was examined in a control urine solution, as opposed to PBS (e.g. Figure 22). As 
no studies have been identified that have attempted to detect SpA in urine by WB, this is a 
novel observation. Previous work on WB development for the detect Staphylococcal toxins 
by Frances Price (MSc 2013), showed no attenuation in the signal of purified toxin in control 
urine compared to PBS.80  
We theorised that a component of control urine may be contributing to the reduced signal, 
as both urine and PBS SpA samples were prepared identically and to the same 
concentration. A molecule which is known to bind to SpA and is present in healthy urine is 
IgG, which is also found along with small amounts of IgA and IgD.191 SpA ELISA results show 
that there is approximately 0.4-0.5µg/ml IgG in the control urine used for creating WB 
samples. The interaction between SpA and IgG may affect the ability for anti-SpA antibodies 
to bind to the protein once transferred to membrane, potentially reducing signal on WB. 
However, the mechanism by which this effect occurs following heating and coating of 
samples in SDS, which should eliminate SpA-IgG bonds, is not known. It was decided to 
attempt to replicate the potential quenching effect of IgG on SpA, in PBS. 
Despite the repeated observation of a quenching effect in control urine, this was not 
reproducible by adding 1µg/ml commercially sourced human IgG to sterile PBS samples 
containing SpA. This result confirms that a collection of human IgG, at higher concentrations 
found in urine, is unable to reproduce this effect. Further experiments demonstrated that 
patient urine, which can contain up to 10 times the amount of IgG than healthy urine (as 
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demonstrated by WB and ELISA), showed no quenching effect on samples when spiked with 
SpA (Figure 19- 20). Ultimately, this attenuation in SpA signal was not reliably reproduced by 
WB of patient samples, and IgG levels did not appear to influence the effect. It was decided 
that we could not conclude the reason for this difference in signal between different 
standard solutions. 
4.1.3 Optimal blocking and antibody solution for Protein A detection 
In WB method development, important factors to consider are the blocking buffer, and the 
subsequent concentration of antibody solution, which is constituted in the same blocking 
solution. These factors proved to greatly influence the sensitivity and specificity of the WB 
technique developed to detect SpA. 
Firstly, blocking solution was compared in WBs of commercial SpA, between BSA (2% (w/v) 
or 5% (w/v)) and 5% (w/v) milk. BSA was initially chosen as the blocking and antibody 
solution of choice, due to its purity; it is made up of a single serum protein as opposed to 
milk, which is a mixture of proteins and other macromolecules. Literature evidence also 
shows that milk, due to the presence of casein, could interfere with the detection of 
antibodies by ECL.190 During initial WB experiments detecting purely SpA standards, BSA-
blocked membranes demonstrated lower background signal. However, when adapting the 
method to testing patient samples, it was revealed that blocking and incubating in 5% (w/v) 
milk greatly reduced the additional bands seen in patient samples. This was restricted to 
ladder proteins and patient urinary proteins, with 0.1µg/ml SpA standards still displaying 
strong signal (e.g. Figure 38). By exchanging milk for BSA in the antibody incubation stage of 
WB, we developed a specific test for SpA. 
Literature describing this increased blocking potential of milk is scanty, with most sources 
describing equal efficacy for both milk and BSA as blocking buffers,190  or reduced 
background and increased sensitivity when using BSA.192 However, we found that the 
elimination of non-specific binding was only seen when milk was used as antibody solution 
(not blocking specifically). Milk may be responsible for this effect in a number of ways: 
1. Increased variety of proteins in milk- as stated, milk contains a mixture of proteins, 
including casein and lactoglobulin, which allows a greater variety of blocking sites. 
Given the wide variety of potential proteins in patient urine, including plasma 
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proteins, immunoglobulins and enzymes, this may make milk a very effective 
blocking substance for WB of this matrix. 
2. Competitive binding with anti-SpA antibody- as we have demonstrated, the 
reduction in non-specific binding does not occur during the blocking stage, but is 
specific to the antibody incubation stage. This implies a degree of interaction with 
anti-SpA for the blocking effect to be achieved, which could be of a competitive 
nature. Anti-SpA may be directly inhibited from non-specific binding sites by the 
presence of milk proteins, or, it may be that anti-SpA antibodies bind to a milk 
protein preferably to the non-specific urinary proteins. Given that that the sensitivity 
of the WB for SpA standards remained unchanged by incubating antibody in milk, 
the level of interaction between milk protein and antibody would have to not 
interfere with commercial SpA binding. 
4.2 Detection of Protein A by Western Blot- sample experiments 
When applying the optimised SpA WB method to testing patient samples, it was decided to 
perform screening experiments, using a sample from each patient, followed by in-depth 
experiments on certain patients most likely to produce positive results. Following this series 
of WB tests, no positive detection of SpA was achieved, meaning no bands of proteins were 
detected in patient samples, at the correct MW for commercial SpA, or at any other MW. 
During initial screening, using BSA as blocking and incubating solution, multiple bands of 
different MW were detected in patient samples (e.g. Figure 25- 26), which showed promise 
that SpA might be present in some form in patient urine. However, for these bands to be 
SpA, it would have to be at a variety of MWs not documented in the literature.  The highest 
estimate for S. aureus toxin rates in the same patient samples was 72% (specifically for 
Staphylococcal AH),80 and as almost every patient sample displayed a band using the non-
optimised WB method, these additional bands were unlikely to all represent a form of SpA. 
This was confirmed during optimised testing (using milk), as none of these additional bands 
were detected, in any patient sample. 
The lack of detected SpA, even those later found to be positive on SpA ELISA, can have 
arisen for a number of reasons. Firstly, there may be no SpA present in these samples. This 
is a likely eventuality, as corroborating evidence (e.g. LC-MS) also concur that no SpA is 
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present in patient samples. However, given a reliable detection limit of 0.1µg/ml (~7ng) SpA, 
it may be that SpA is present, but at limits below that which is detectable by WB. 
Physiological levels of regular urinary proteins (e.g. albumin) is around <300µg/ml,193 but 
bacterial toxins and other excreted products can be significantly lower; Harrison et al 
estimated levels of Staphylococcal toxins in the range of nanograms to picograms (e.g. 1-
0.1ng).79 If SpA is present in samples at the picogram level, then our WB method would not 
have sufficient sensitivity to detect it. 
Some patient samples were later estimated to contain levels of SpA which approach the 
detection level of WB, such as patient 13, indicating that SpA bands could be detected by 
WB. This patient’s sample range demonstrated an ELISA result corresponding to a level of 
approximately 15ng/ml (1.5ng total), but a repeat WB of this patient samples did not yield 
any positive bands. 
Finally, it may be the case that SpA is present in patient urine at appropriate levels for WB 
detection, but in an altered form or variant which is unable to bind to the primary antibody 
used. Given the previously discussed range of SpA variants, depending on strain and protein 
secretion method, it may be that SpA is present in urine in one such form. Using a primary 
antibody known to bind to a different epitope of SpA may be helpful in ruling out this 
eventuality.  
4.2.1 Optimal sample preparation and method 
A series of experiments were carried out in order to optimise the preparation of patient 
samples for WB testing, to allow an effective screening process for SpA. This process 
elucidated important information about the patient samples which were carried into the 
screening and testing. 
Many patient samples carried a substantial amount of solid material suspended in the urine. 
This is seen amongst urine collected from patients on ICU wards, due to sloughed material 
from the urinary tract, as well as contaminant material from urinary catheters. However, it 
was not clear as to how to prepare samples containing substantial material; either the solid 
was to be avoided, to reduce non-specific protein contamination of WB, or it should be 
mixed in with the liquid urine, to obtain greatest chance of detecting SpA. We carried out an 
experiment testing these two methods of preparation found that the vast majority of 
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material detectable by SpA WB, which was later thought to be mostly non-specific proteins, 
is contained within the solid particulate matter. It was decided that in order to give the best 
chance of finding SpA in patient urine, this proteinacious material should be incorporated in 
WB samples, by vortexing. SpA, if present in patient urine, may have been bound to a 
number of antibodies, which may have experienced aggregation with other proteins in the 
samples. This method of sample preparation also extended to SpA ELISA sample application, 
and LC-MS sample analysis. 
4.3 Conclusions from Western Blots 
An effective and specific WB method, developed to detect commercial SpA, was unable to 
detect any positive results in a wide range of patient samples which had previously shown 
to be positive for AH, SEB, SEC and TSST-1 by WB methods. This does not rule out the 
presence of SpA in these samples, or in its presence in urine in a form undetectable by WB. 
The development of an ELISA with higher sensitivity for SpA would aid in interpreting the 
negative WBs. 
4.4 Detection of Protein A by ELISA 
An ELISA method was developed for the detection of SpA, utilizing the strong SpA-IgG 
binding affinity, by using IgG as capture antibody, followed by detection of IgG bound SpA 
by use of anti-SpA antibody. During optimisation, it was found that primary antibody at 
1:4000 concentration, and using milk as a blocking agent and antibody solution, lead to the 
greatest useful range of SpA detection. Using this method, we were able to detect 
commercial SpA diluted in both PBS and control urine; this was a sensitive and specific test 
for SpA, with a linear detection range of 0.78-25ng/ml SpA. Background, in both PBS and 
control urine, was consistently low. 
Screening of patient samples by this method was promising, with 25% of patient samples 
displaying an increased absorbance, the majority containing potentially low levels of SpA, 
e.g. 1-5ng/ml. In each ELISA microwell, 100µl of sample is added for testing, meaning that 
the total amount of SpA potentially being detected in sample is one tenth of this 
concentration, equalling 0.1-0.5ng. These protein levels are in keeping with physiological 
levels of Staphylococcal toxin found in patient urine by work carried out by Harrison et al,79 
and Frances Price (MSc 2013).80 Not only did concentrations of antigen correspond to 
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previous studies, but the percentage of positive samples fell within the range of samples 
estimated to be positive for other Staphylococcal toxins (5.9-72%).80 If these results were 
proven to be specific for low levels of SpA, this represents a sensitive technique for 
detecting a Staphylococcal surface protein in a novel matrix. 
However, we were aware of a number of methodological shortcomings which may call into 
question the specificity of this ELISA. These include the use of a mixture of human IgG as 
capture antibody, and detecting SpA with a primary anti-SpA antibody known to be capable 
of non-specific interaction with urinary proteins (shown on WB). This raises the suggestion 
that the positive results we see on SpA ELISA may be due to non-specific interaction, which 
prompted a series of experiments to confirm the specificity of this SpA ELISA method. 
4.4.1 Tests of protein and IgG content 
Unlike using an antigen specific antibody, using IgG as capture antibody means that a 
number of different proteins capable of binding to IgG, could be present in the microwell 
plates when primary antibody is added. This presents the chance of non-specific binding, as 
human IgG is capable of binding to a host of antigens and proteins. In order to find out if the 
presence of additional proteins attached to IgG is the cause of the increased absorbance on 
SpA ELISA, an experiment was carried out to estimate the levels of the two most likely 
candidates causing cross-reactivity; IgG and total protein. 
Following a further stage of method development, an IgG ELISA was underdone which 
measured directly adsorbed IgG (direct ELISA). Interestingly, the initial section of our 
method development discovered that using SpA as a capture antigen for IgG, which has 
been suggested as efficacious by other studies,194 proved to be non-specific and unreliable 
for commercial IgG estimation. 
A select number of patient samples were collated, based on previous ELISA results, in order 
to test a cohort of the most positive patient urine samples on a single microwell plate, as 
well as negative patient controls. These same patient samples were retested for SpA, along 
with a fresh test for IgG and total protein content. We identified no statistical difference in 
IgG and total protein absorbance between positive and negative patient SpA groups. The 
sample size for each group was small (n=15 positive group, n=18 negative group), lending 
these tests limited statistical power. Despite this, it was found that certain samples with 
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large amounts of IgG and protein displayed very little absorbance on SpA ELISA, confirming 
that the positive results seen on this ELISA were not solely influenced by these factors. We 
propose this as evidence of a high specificity of the SpA ELISA method, and if the positive 
SpA ELISA results are in fact the result of antibody cross-reaction, this is likely due to a 
specific urinary protein, not level of total protein or IgG. Further work needs to be done in 
order to confirm the specificity of the anti-SpA antibody, and therefore confirm the SpA 
ELISA as a viable test. 
4.4.2 ELISA of boiled samples 
As discovered from previous WB and ELISA, as well as the literature, IgG is present in both 
healthy and patient urine. Previous studies have theorised that the presence of IgG in 
human samples, such as serum, interferes with immunoassays for SpA by binding to SpA and 
blocking binding sites.183, 184 We were able to corroborate these findings by attempting to 
detect SpA in healthy human serum, which showed a large quenching effect, large enough 
to almost completely mask the SpA in the serum (Figure 63). The absorbance of SpA 
standards became co-incident with PBS standards following boiling of the serum SpA 
samples, which would provide the energy to break apart SpA-IgG bonds. This quenching 
effect was seen at a greatly reduced level in control urine, but an increase in sensitivity was 
still observed following boiling of urine (Figure 62).  
So far, this information was consistent with the nature of SpA-IgG binding, though this 
proves that saturation of SpA binding sites can occur in IgG solutions, and this effect is dose 
dependent. Also, importantly, these boiling experiments proved that the commercially 
sourced SpA used to create the standard ELISA curve is heat resistant. When ELISA-positive 
patient samples were boiled, we expected to see either an increase, or no change, to 
absorbance of patient samples. As our ELISAs show, this did not occur, and all patient 
samples became uniformly negative following boiling. This means that the molecule, or 
protein, which was causing the raised absorbance, was denatured fully after boiling after 3 
minutes. 
We propose that any SpA produced during the course of infection should remain heat 
resistant following excretion into urine; therefore, the positive ELISA results are most likely 
not due to the presence of SpA. 
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This leads to the primary question arising from our ELISA results; what have we detected by 
this technique, if not purely SpA? The most likely answer is a different protein which is 
denatured by boiling, but other options include particular antibody complexes or whole 
cells, or cell fragments. If these are present in the urine, unaltered, they can be immobilised 
by IgG in the first step of the ELISA, and subsequently picked up non-specifically by anti-SpA. 
The substance which is binding to both the IgG and anti-SpA in the ELISA, is unlikely to be a 
pure form of SpA released by S. aureus infection, a conjecture which is backed up by the 
results of both LC-MS of positive samples, and also statistical analysis displaying a lack of 
association with infective status. 
4.5 Protein A detection by LC-MS 
By using LC-MS techniques, our aim was to rule out, or confirm, the presence of SpA in 
patient urine samples, by using targeted in-gel digestion sample preparation. By excising 
and digesting visible bands of commercial SpA on an SDS-PAGE gel, we were able to 
confidently identify SpA. These data confirmed the viability of an in-gel digestion method for 
detecting Staphylococcal toxins, and also identified the presence of SpA variants, of differing 
MW, contained within the commercial SpA product. This confirmed previous speculation on 
the cause of the SpA double-band consistently seen on WB. 
Following this positive identification of the target protein, we tested a range of patient 
samples by excising bands at the approximate MW of commercial SpA. This targeted 
approach aimed to avoid the detection of more abundant urinary proteins, present at 
different MWs. However, none of the sample analyses by LC-MS provided identification for 
SpA, including testing whole samples which were positive by ELISA. The lack of detection 
could not be attributed to preparation or processing errors, due to the identification of 
commercial SpA and BSA, analysed concurrently with samples, as well as significant 
detection of known urinary proteins such as albumin and alpha 1 acid glycoprotein 
(orosomucoid) in the patient samples themselves. 
The method devised to test full samples, using a limited amount of electrophoresis to create 
a single large band of all proteins, allowed the identification of most abundant proteins in a 
sample. This did not detect SpA, only finding E. coli proteins at significant levels. These 
proteins may be from the urinary tract, urinary catheter or catheter bag, or from 
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contamination while handling samples. Waiting time between sample preparation and 
processing by MS was minimal (<1 day), so it is unlikely to be from Gram-negative growth 
from storage. This full sample testing method provides a promising route of investigation for 
urinary Staphylococcal antigens. However, to take full advantage of this method, a machine 
capable of detecting proteins at very small concentrations would have to be used.  
The use of LC-MS in indentifying Staphylococcal toxins is a technique used extensively in the 
investigation of the S. aureus proteome, using either in-gel digestion techniques, or whole 
cell culture sample digestion, to catalogue the proteins found in bacterial culture.195 The use 
of LC-MS to detect antigens in human samples has not been studied extensively, so could 
represent a potentially fruitful area of research. However, the presence of other bacterial 
proteins from the urinary tract or, or contamination from handling of samples, as well as the 
large amount of other urinary proteins, are issues which complicate the detection of scarce 
bacterial toxins. 
4.6 Statistical Analysis 
A basis for statistical analysis on the patient cohort was formed by characterising ELISA 
results as positive (1) or negative (0), based on a cut-off absorbance of 0.100, which would 
correspond to a hypothetical concentration of 0.1ng/ml SpA. Using this cut-off absorbance 
was deliberately high (>10 SD away from background absorbance), due to the likely chance 
of non-specific antibody interaction marginally raising absorption. Choosing a high cut-off 
was a strategy to avoid potential false positive results being analysed within the SpA positive 
group. This created a positive group of patient samples, which consisted of 25% of samples 
tested. Statistical analysis, performed by dichotomisation of samples into positive and 
negative and testing mean difference, would help to highlight any factors which may be 
contributing to a raised absorbance in these samples. Identifying a relationship between 
SpA ELISA result and infective status of patient was also an important aim for this research. 
To achieve this, markers of infection (HR, RR, BP, temperature, pH, WCC and CRP) were 
compared between the two groups, then analysed by Student’s T-test and logistic 
regression. Results showed no significant differences between the 25% of patients with 
positive ELISA and the rest of the sample population. As the raised absorbances seen on SpA 
ELISAs are strongly suspected to be of a non-specific nature, these findings are further 
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indication of these results being false positive. Previous work on this patient cohort, by 
Frances Price (MSc 2013) had revealed a weak association between markers of infection and 
presence of Staphylococcal toxins (particularly AH). This is in keeping with previous work on 
ICU patient status and urinary Staphylococcal toxins, by Azuma et al, which found a greatly 
increased incidence of toxins in patients with confirmed sepsis (42%), compared to other 
diagnosis (6%).76 Based on this, it should be expected that a positive SpA ELISA, detecting 
endogenous SpA, would relate to increased markers of infection. However, this particular 
patient group was collected from a general ICU population, without prerequisites for sepsis 
or infection, making the relationship of the ELISA results to infective status difficult.  
However, despite small patient numbers with an infectious diagnosis (n=22, 49% of total 
samples), and a smaller number with confirmed sepsis (n=6, 13% of total samples), limited 
conclusions can be drawn based on this diagnostic information. These mostly concur with 
the absence of SpA in patient urine. Of the 6 patients with confirmed sepsis, 3 produced 
samples with a significantly raised ELISA result. Two patients at highest risk of S. aureus 
infection, 18 (Gram-positive blood culture) and 24 (Gram-positive wound swab), were 
negative for SpA in all modes of testing; WB, ELISA and LC-MS. The patients with the most 
positive ELISA results, 13 and 36, were admitted with non-infectious diagnosis, diabetic 
ketoacidosis and bowel perforation respectively. Admittedly, these are single case examples 
and a number of factors could have influenced this pattern of ELISA results (e.g. urinary 
contamination, infection during ICU admission), but does provide some evidence against the 
SpA ELISA for predicting S. aureus infection in the ICU setting. 
Statistical analysis did reveal a significant association between the positive ELISA result 
group, and evidence of renal failure, including raised serum urea, creatinine and a reduced 
eGFR. This could be a result of antigen deposition in the kidneys, an event which is known to 
occur with Staphylococcal toxins,196 TSST-1,197 and also Streptococcal toxins.198 This leads on 
to the prospect that the anti-SpA antibody used in ELISA is detecting SpA in a form of SpA-
IgG complexes, which are known to form in response to SpA in the bloodstream.175, 176 These 
would be large molecules, which would only be able to be excreted in the event of 
glomerular basement membrane leakage. However, for this to explain the our positive SpA 
ELISA results, it would depend on the SpA-IgG complexes being detected by an anti-SpA 
antibody, but not the unbound SpA molecule which would be released by boiling. We 
SID: 33007675                                                                                                                        Christopher Varley 
125 
 
believe this is unlikely, as it would involve the alteration of the SpA molecule by interaction 
with IgG, which is not known to occur. 
It has been shown that proteinuria, caused by damage to the glomerular basement 
membrane, increases over the course of chronic renal failure,199 as well as being a direct 
result of kidney damage in diseases such as acute tubular necrosis.200 As we have clear 
evidence of the lack of SpA in patient urine from WB, and to a more limited extent, LC-MS 
results, the presence of proteins causing non-specific binding is the more likely explanation 
for the link between raised absorbance in SpA ELISA and markers of renal failure. 
4.7 Limitations of this study 
Given the negative outcome of this study in terms of identifying a novel antigen target for S. 
aureus infection status, it is important to highlight areas in which research required 
improvement, before ruling out SpA as potential testing candidate. While we have 
developed a sensitive and specific ELISA, as well as a specific (but less sensitive) WB, certain 
aspects could be improved to optimise these methods further. 
4.7.1 Antibody specificity 
As demonstrated during the WB method development, and during preliminary work by this 
laboratory, polyclonal HRP-conjugated anti-SpA antibodies have the potential to exhibit 
extensive non-specific binding to various proteins which may be found in patient urine. 
While through the process of this research we were able to remove much of this effect in 
WB, through the use of lower amount of antibody diluted in 5% (w/v) milk, there remained 
the possibility that non-specific binding could have been reducing the sensitivity of the WB 
technique. The use of an HRP-conjugated primary antibody (‘direct detection’ WB) could 
also be associated with reduced sensitivity as signal amplification is less pronounced 
without the use of a primary-specific secondary antibody.201 However, using a secondary 
antibody (such as HRP-conjugated anti-rabbit IgG), has been associated with an increased 
background and increased likelihood of non-specific binding.202 It was decided that the 
detection of SpA on WB to a concentration of 0.1µg/ml (7ng per sample), was a sensitive 
enough detection level to rule out the presence of SpA, however, we were unable to rule 
out whether an indirect WB method would provide a greater level of sensitivity. 
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In the ELISA experiments, antibody specificity is likely to have contributed to the raised 
absorbance results seen in patient samples. Due to the lack of protein separation by SDS-
PAGE electrophoresis, a positive result seen in ELISA may be due to high-protein levels in 
the samples, especially in ICU patient urine. Because of this lack of protein differentiation, it 
has been recommended that ELISA is best utilised when using an antibody with high 
specificity to the target antigen.203 As the antibody used in these experiments has shown to 
be capable of exhibiting non-specific binding, it would be difficult to rule cross-reaction as a 
complicating factor in interpreting results. Further experiments to demonstrate the 
specificity of a variety of anti-SpA antibodies, monoclonal and polyclonal, would be required 
in order to improve the development of an effective SpA ELISA method. 
The direct comparison of antibody binding in WB and ELISA is difficult due to the differences 
in sample preparation between the methods. Antibody-binding in ELISA samples occurs in 
more natural conditions than in WB; this is due to the SDS-coating process which is integral 
to the separation of proteins on SDS-PAGE. During WB sample preparation, SDS binds to 
hydrophobic regions on proteins and induces ‘reconstructive denaturation’, forming 
proteins into alpha-helices.189 While it may be that the anti-SpA would have had more 
available sites of binding in WB samples due to this denaturation process, unaltered urine 
may have contained more large contaminants, such as complexes, biofilms or whole cells, 
which may have facilitated antibody binding, or produced false positive ELISA results. 
Regardless of sample preparation, the fact remains that the primary antibody used was a 
polyclonal IgY, meaning the potential exists for a monoclonal anti-SpA antibody to be more 
specific, if not necessarily more sensitive. 
4.7.2 Patient sample group 
For this research, as well as the earlier work by Frances Price (MSc 2013), 305 urine samples, 
from 46 patients, were collected for this research from the local ICU ward at Royal Lancaster 
Infirmary. In order to test potential candidate molecules for S. aureus antigen testing, a wide 
selection of patients, with varying diagnoses, was included in the sample series. However, 
despite providing the opportunity to test antigen levels in a realistic hospital population, it 
may be the case that the amount of samples available to test did not provide a higher 
enough incidence of S. aureus bacteraemia or transient colonisation, in order to detect SpA 
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in sufficient quantities. Previous published work on detecting an antibody response to SpA 
in serum has been limited to patients with confirmed S. aureus endocarditis,186 which would 
guarantee the highest chances of detecting Staphylococcal toxins.  
To fully assess the data found by this research, the small sample size must be taken into 
account. A relatively small number of patients, and specifically from the ICU department, 
may limit generalisation to the rest of the hospital, or general, population. 
Roughly 80% (241) of the available samples were tested by ELISA, and substantially less by 
LC-MS, which was primarily undertaken in order to confirm the constituents the urine 
samples which were positive on ELISA. While we can be reasonably confident that our ELISA 
results are influenced by non-specific antibody binding, in order to confirm the absence of 
SpA in the ICU patient samples, a more complete screening of samples, using the LC-MS 
method capable of detecting proteins of low concentration, would need to undertaken.  
4.7.3 Mass spectrometry sensitivity 
Interpreting LC-MS data, specifically the ability to rule out the presence of SpA in patient 
urine samples, must take into account the sensitivity and resonance of the MS machine. The 
sensitivity of the instrument used in this research was capable of generating an 
identification score of >1000 for BSA, when a sample of 1.5pmol of BSA was analysed, 
indicating a very high sensitivity. Positive identification (e.g. scores of ~100-1000) of very 
small amounts of a target molecule could be ‘masked’ by the abundance of other proteins 
within the samples. This ability to discern wide ranging concentrations of proteins in a 
sample is known as the dynamic range. Unfortunately, this figure is low in our MS 
instrument, measuring approximately 102 to 103, meaning any molecule with concentration 
less than 1-0.1% of a sample will not be (significantly) detected. This represents a significant 
problem in interpreting MS data of full patient samples, given the amount of total proteins 
present in some samples, hence the requirement to run samples on an SDS-PAGE gel and 
excise the band of desired MW range. While this may reduce the amount of additional 
protein in a sample, the problem of SpA variants of different MW going undetected remains 
an issue. 
Also of concern is the MS resonance, which is the degree in which peaks of similar weight 
can be distinguished as separate proteins. As commonly identified urinary proteins include 
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albumin (MW 66kDa) and orosomucoids (MW 22-25kDa), there is reduced chance of 
interference with the entire SpA protein (MW 50-55kDa). However, if SpA is present as a 
smaller breakdown product, or in a variant at different MW, the MS resonance may be 
playing a role in the negative SpA identification seen. 
As such, our findings from LC-MS data should be analysed with the detection limits of the 
machine taken into account, when confirming, or ruling out, the presence of a protein. This 
is particularly the case in test solutions containing a high number of additional proteins, and 
if the target protein or toxin is believed to be present at very low concentrations (e.g. 
nanograms). 
4.8 Wider Implications 
In an attempt to locate SpA in ICU patient urine by a variety of commonly used biomedical 
techniques, we have developed a sensitive and specific WB for SpA, a sensitive ELISA for 
SpA, and a method for screening patient urine samples for bacterial proteins through in-gel 
digestion and LC-MS. Despite this, we have been unable to detect any SpA by WB and LC-
MS, or confidently rule out the chance of false positive ELISA results.  
Previous work, by other groups and this laboratory, has revealed the presence of 
Staphylococcal toxins in the general and hospital population. Healthy infant urine displayed 
a pyogenic toxin rate of ~10%,79 indicating early exposure to S. aureus, while Frances Price 
(MSc 2013) found a high proportion of exotoxins in the same cohort of ICU patients, 
especially AH (72%).80 If these results are indicative of S. aureus colonisation or infection, 
then SpA should be present in these same patients. Aside from methodological factors, such 
as non-specific binding, the fact that these results do not correlate with previous findings 
may be due to: 
 Lack of urinary excreted SpA-  SpA is shown to induce IgG antibody responses in the 
host, which increase rate of SpA elimination from the bloodstream,175 and is known to 
involve primarily the liver and spleen.174 These are common sites of phagocytosis, which 
serves the function of removing unwanted serum components, the breakdown products of 
which are able to be excreted in the urine. However, it may be the case that SpA is entirely 
digested in the liver and spleen, and the eventual excreted product bears no resemblance to 
the original SpA molecule. SpA-IgG complexes are too large (~200kDA) to pass through the 
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intact glomerular basement membrane, so it is reasonable to suggest that most SpA goes 
through a stage of processing before eventual secretion.  
 
 Low production of SpA by S. aureus- studies attempting to quantify the amount of 
SpA produced by S. aureus strains are limited, however, an early study produced a figure of 
1.6% of cell culture mass of S. aureus, which gives an indication that production can be 
significant.104 However, different S. aureus strains produce variable amounts of SpA,135 
making the possibility that even if infection was present, sufficient quantities of SpA might 
not be released in order to be detectable. Genetic control of SpA production indicates that 
there is up-regulation of SpA during times of low bacterial load,204 which implies that SpA 
may be found in higher proportions during early infection or healthy colonisation. However, 
levels may also rise during times of Staphylococcal cell lysis (releasing cell wall SpA), and 
secretion of SpA also differs between strains.106 Therefore is it difficult to accurately suggest 
when during the course of S. aureus infection SpA production is maximal. 
4.9 Future work 
Previous discussion has illuminated areas of this research which could be continued, along 
with new areas of research which would provide more information on the presence of SPA 
in the human body. For example, the SpA WB developed by this research could be extended 
to testing urine from different patient populations, where the concentrations of SpA may be 
significantly higher, such as S. aureus soft tissue infection or endocarditis patients. The 
concurrent collection of serum and urine samples from such patients would allow the 
testing for SpA in both, in order to learn more about SpA excretion from the body. 
4.9.1 Further patient sample testing 
While the search for SpA in ICU patient urine may have proved ineffective by WB, future 
work could focus on ELISA of other patient samples, given the increased sensitivity of this 
method. Evidence in the literature proves that antibody responses to SpA can be elucidated 
in the bloodstream of bacterial endocarditis patients, using a sensitive and specific ELISA 
technique for anti-SpA.186 This demonstrates that SpA, either extracellular or cell-wall 
bound, is located in the bloodstream during active infection. Furthermore, the ability for S. 
aureus, particularly antibiotic resistant strains, to secrete SpA,117 provides a basis for more 
widespread serum testing .The ability to detect an antibody response, or to directly detect 
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SpA, in the serum of ICU patients could provide a viable biomarker for the presence of S. 
aureus in the bloodstream.  
As our patient population contains no confirmed S. aureus bacteraemia or sepsis cases, this 
research would involve the collection of serum samples from patients with these conditions. 
Development of WB and ELISA tests optimised for anti-SpA in serum could also be 
developed, though this matrix may prove more difficult than urine due to high protein 
content of serum samples. 
However, the potential benefits of a serum SpA test are great; the identification of SpA, or 
response to SpA, in the bloodstream could provide rapid information on the presence of S. 
aureus in the actual location of importance in sepsis, bypassing the need to take renal 
excretion into account. Aside from diagnostic information, the frequent use of invasive 
interventions on ICU wards exposes patients to the risk of bloodstream infection, and a 
rapid serum test for SpA could prove valuable in determining if S. aureus exposure has 
occurred. However, the disadvantage of a serum test is the invasive route required for 
sampling, over the ease and non-invasive nature of urine testing. 
Another potential candidate for future sample testing would be nasal isolates taken from 
ICU patients, followed by culture and WB testing for SpA. As ~30% of the population is 
colonised by S. aureus at any one time,205 this could provide useful quantification 
information into SpA production in patient ICU population, compared to the general 
population. 
4.9.2 Continued mass spectrometry of patient samples 
The LC-MS method developed to test entire patient samples (e.g. Figure 63- 64) carries 
potential for cataloguing the constituents of the unique subset of ICU patients. The samples 
tested in this research revealed a number of human proteins traditionally found in urine, as 
well as some significant evidence of E. coli proteins. As discussed, these may be due to 
contamination, either from sample preparation or from the storage and collection of urine 
from the catheter. However, these preliminary findings prove the potential effectiveness of 
this LC-MS technique in screening this sample population for bacterial toxins, if features 
such as dynamic range and resonance are improved. 
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Future work could aim to establish the presence of other infectious biomarkers by MS, and 
determine whether these relate to, or predict, infection status. Ideally, these samples 
should be analysed with an LC-MS machine with greater ability to detect proteins of lower 
concentration. Follow up experiments could attempt to confirm these markers using the 
biochemical tests used in this research; WB and ELISA. 
5 Conclusion 
Staphylococcus aureus is a common cause of serious infection on Intensive Care wards, and 
ensuring prompt treatment of bloodstream infection is important in avoiding potentially 
fatal outcomes. Techniques involving urinary testing by ELISA have allowed swift diagnostic 
tools for a variety of infections, such as pneumococcal and Leigionella pneumonia.73 Recent 
research by this laboratory has revealed the presence of Staphylococcal toxins and 
superantigens in ICU patient urine using similar techniques. We decided that it would be 
beneficial to test these samples for the presence of additional Staphylococcal antigens, with 
the aim of ascertaining whether a suitable diagnostic test for S. aureus infection could be 
developed in the future.  
Staphylococcal Protein A is an abundant surface protein found in almost all S. aureus strains. 
It has been shown to play a role in overt S. aureus infection and also promoting healthy 
carriage of the organism,205 and it is conceivable that its detection in urine could provide a 
marker for these conditions. 
 Our aim was to develop methods for detecting SpA by Western Blot and ELISA. These 
laboratory techniques were optimised for the detection of commercial SpA spiked in buffer 
and urine, which included work to reduce the cross-reactivity of anti-SpA antibody. 
However, when our optimised Western Blot was performed on patient urine sample ranges, 
we could not detect bands at a MW which could correspond to SpA.  
Subsequently, an effective ELISA using IgG as capture antibody was developed, which 
proved more sensitive than Western Blot, allowing detection of SpA levels as low as 
0.78ng/ml (0.07ng total SpA). Once applied to patient sample screening, this technique 
identified a raised absorbance level in approximately 25% of the ICU urine samples, 
suggesting the presence of SpA. However, follow-up experiments indicated that non-specific 
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binding of SpA antibody may have contributed to the increased absorbance levels seen in 
these samples. For example, whilst commercial SpA spiked samples retained their levels of 
SpA following heat treatment, in the positive patient samples, SpA levels appeared to 
entirely disappear on heat treatment. Additionally, LC-MS analysis of the same patient urine 
samples could not identify SpA. It could be the case that our ELISA technique has detected a 
heat sensitive SpA variant in the positive samples, or, more likely these results are due to 
non-specific binding to abundant urinary proteins. 
A potential reason for our inability to detect SpA in the urine could be that SpA binds to 
plasma IgG, generating SpA-IgG complexes, which have an approximate MW of 200kDa. 
Interestingly, statistical analysis revealed that while a positive SpA ELISA result did not 
significantly correlate with patient markers of infection, there was a correlation between 
SpA detection and evidence of renal failure, specifically raised serum creatinine and urea, 
and lowered eGFR. It appears that kidney dysfunction has led to positive ELISA results in 
these patients, conceivably because of increased passage of SpA-IgG complexes, or simply 
total protein, through damaged glomerular membranes.  
Limitations of this study include the small sample size (<241 samples). While we can infer 
that our positive ELISA samples may be the result of non-specific interaction of the SpA 
antibody, investigation of a wider range of patient samples would allow us to add weight to 
this suggestion. We could also employ different anti-SpA antibodies in Western blotting and 
ELISA to see if these allow a more sensitive detection of SpA in our positive samples, or 
whether they confirm absence of SpA in these samples.  
Using optimised immunoblotting and immunoassay techniques, the Staphylococcal surface 
protein SpA has been determined to currently be an elusive candidate for these methods of 
testing in a general ICU patient cohort. This research presents opportunity for future work 
to investigate the primary route of excretion of SpA, with S. aureus diagnosis through SpA 
testing a viable opportunity for future research. The focused collection of additional patient 
serum and urine samples with known S. aureus bacteraemia would provide useful 
confirmation of these methods. Attempts to identify potential markers of Staphylococcal 
infection are rare in the literature, despite the great need for improving our knowledge of, 
and management of, this disease. 
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Patient diagnosis and characteristics.  
Patient number- 45 
Patient number Diagnosis on 
admission 
Age Death during 
admission? 
1 Addisonian Crisis 77 N 






4 Hodgkin’s Lymphoma 19 N 
5 Ruptured Aortic 
Aneurysm 
73 N 
6 Viral Encephalitis 67 N 
7 Trauma 40 N 
8 Spinal Cord Ischemia 54 N 
9 Urinary Sepsis 67 N 
10 Acute Kidney Injury 61 N 
11 Pneumonia 64 N 
12 Bowel Perforation 80 N 
13 Diabetic Ketoacidosis 37 N 
14 Ventilation Acquired 
Pneumonia 
30 N 
15 Gram-negative sepsis 71 N 
16 Pneumonia 82 N 
17 Ischaemic Bowel 86 N 
18 Not Known 54 N 
19 Necrotising Fascitis 48 N 
21 Perforated Stomach 18 N 
22 Pneumonia 77 N 
23 Deep Vein Thrombosis 25 N 
24 Necrotising Fascitis 72 N 
25 Ischaemic Bowel 67 N 
26 Sepsis 63 Y 
27 Not Known 38 N 
28 Caecal Volvulus 46 N 




31 Pneumonia 74 N 
32 Multiple Organ Failure 37 Y 
33 Pneumonitis 77 Y 
34 Sepsis Not collected Y 
35 Pneumonia 35 N 
36 Bowel Perforation Not collected N 
37 Diabetic Ketoacidosis 69 N 




For further patient details, the following information is available in Frances Price (Msc 
2013):80 
 Vital Signs: 
o Heart rate 
o Blood pressure 
o Temperature 
o Respiratory Rate 
 Ventilation 
o Invasive/ Non Invasive 
 Invasive lines and catheters: 
o Central Venous Catheter 
o Arterial Catheter 
o Urinary Catheter 
o Abdominal Drain 
o Chest Drain 







39 Pneumonia 65 Y 
40 Meningitis 56 N 
41 Pneumonia 83 N 
42 Sepsis 70 N 
43 Necrotising Fascitis 33 N 
44 Pancreatitis 46 Y 
46 Sepsis 34 N 
47 Gram-negative Sepsis 76 N 
